Regulation of the Pro-Tumorigenic Senescence-Associated Secretory Phenotype by Flanagan, Kevin
Washington University in St. Louis
Washington University Open Scholarship
Arts & Sciences Electronic Theses and Dissertations Arts & Sciences
Spring 5-15-2017
Regulation of the Pro-Tumorigenic Senescence-
Associated Secretory Phenotype
Kevin Flanagan
Washington University in St. Louis
Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds
Part of the Cell Biology Commons
This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open Scholarship. It has been accepted
for inclusion in Arts & Sciences Electronic Theses and Dissertations by an authorized administrator of Washington University Open Scholarship. For
more information, please contact digital@wumail.wustl.edu.
Recommended Citation
Flanagan, Kevin, "Regulation of the Pro-Tumorigenic Senescence-Associated Secretory Phenotype" (2017). Arts & Sciences Electronic
Theses and Dissertations. 1101.
https://openscholarship.wustl.edu/art_sci_etds/1101
WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology and Biomedical Sciences
Molecular Cell Biology
Dissertation Examination Committee:
Sheila A. Stewart, Chair
Kendall Blumer
Milan Chheda
Robert Mecham
Joshua Rubin
Jason Weber
Regulation of the Pro-Tumorigenic Senescence-Associated Secretory Phenotype
by
Kevin Colin Flanagan
A dissertation presented to
The Graduate School
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy
May 2017
St. Louis, Missouri
ii
TABLE OF CONTENTS
LIST OF FIGURES iv
LIST OF TABLES v
ACKNOWLEDGMENTS vi
ABSTRACT ix
CHAPTER 1: Introduction 1
Cellular senescence is a stress-response 2
Senescence plays important physiological and pathological roles 3
The senescence-associated secretory phenotype is pro-tumorigenic 6
The SASP is regulated by multiple pathways 10
OPN is protumorigenic and distinctively regulated 11
The transcription factor C/EBPβ has three isoforms
and regulates the SASP 14
The transcription factor c-Myb is a proto-oncogene 15
References 18
CHAPTER 2: c-Myb is a novel regulatory of the senescence-associated
secretory phenotype 27
Introduction 28
Methods 31
Results 37
Discussion 45
Acknowledgments 48
References 72
CHAPTER 3: p38MAPK plays a crucial role in stromal mediated tumorigenesis 78
Introduction 79
Methods 81
Results 89
Discussion 103
Acknowledgments 105
References 124
iii
CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 129
Conclusions 130
Future directions 133
References 138
iv
LIST OF FIGURES
CHAPTER 2: c-Myb is a novel regulatory of the senescence-associated secretory
phenotype
Fig. 2.1: The senescence-responsive region of the OPN promoter
contains c-Myb and C/EBPβ binding sites 50
Fig. 2.2: C/EBPβ is required for OPN induction in response to senescence 51
Fig. 2.3: C/EBPβ isoform binds SASP promoters in senescent cells 53
Fig. 2.4: c-Myb regulates OPN, IL-6, and IL-8 in response to senescence 55
Fig. 2.5: OPN induction in senescent cells requires c-Myb
binding to the OPN promoter 57
Fig. 2.6: c-Myb and C/EBPβ regulate a subset of the SASP 59
Fig. 2.7: Depletion of c-Myb or C/EBPβ inhibits preneoplastic cell growth
promotion by senescent fibroblasts 61
CHAPTER 3: p38MAPK plays a crucial role in stromal mediated tumorigenesis
Fig. 3.1: p38MAPK activity controls the pro-tumorigenic properties of the
SASP 107
Fig. 3.2: p38MAPK post-transcriptionally regulates the SASP 109
Fig. 3.3: AUF1 directly binds to SASP factor mRNA and modulates
SASP factor stabilization 111
Fig. 3.4: p38MAPK-dependent SASP factors are expressed in TME
of breast cancer lesions 113
Fig. 3.5: p38MAPK inhibition is effective in both senescent fibroblast
and CAF-driven tumors 116
Sup. Fig. 3.1: p38MAPK activity controls the pro-tumorigenic
properties of the SASP 119
Sup. Fig. 3.2: p38MAPK post-transcriptionally regulates the SASP 120
Sup. Fig. 3.3: p38MAPK-dependent factors are expressed in the stromal
compartment of breast cancer lesions 122
vLIST OF TABLES
CHAPTER 2: c-Myb is a novel regulatory of the senescence-associated secretory
phenotype
Sup. Table 2.1: SASP factors upregulated by bleomycin
and Ras-expression 62
Sup. Table 2.2: C/EBPβ dependent SASP factors 69
Sup. Table 2.3: c-Myb dependent SASP factors 71
CHAPTER 3: p38MAPK plays a crucial role in stromal mediated tumorigenesis
Sup. Table 3.1: p38MAPK dependent SASP factors and their overlap
with BC-associated stroma 118
vi
ACKNOWLEDGMENTS
I would like to thank my advisor, Sheila Stewart, for welcoming me into her lab and
supporting me the whole way.  Without her expertise, encouragement, advice, and
direction, I would not have succeeded in my Ph.D. nor learned how to be an effective,
focused researcher.  I would also like to thank the members of my thesis committee
over the course of my research—Kendall Blumer, Josh Rubin, Jason Weber, Bob
Mecham, Milan Chheda, Tatiana Efimova, and Andrey Shaw.  Their expertise and
advice kept me on track and taught me how to approach research questions and
overcome problems.
Thank you to my workplace proximity associates in the Stewart Lab for being my
friends, colleagues, and mentors.  I learned so much from them, starting with Elise
Alspach, with whom I worked throughout her time in lab.  Not only did she lay the
groundwork and begin what became my thesis, she guided me along the way on issues
both technical and bigger picture.  Likewise, I would like to thank Mira Pazolli, Yujie Fu,
Daniel Teasley, Megan Ruhland, Hayley Moore, Bhavna Murali, Shankar Parajuli,
Qihao Ren, and all of the other members of the Stewart lab over the years for their
scientific help, criticism, and making work fun, especially when it otherwise wasn’t.
Each of them contributed to my growth as a scientist and to making graduate school a
better place in their own way. I’d also like to specifically thank my undergraduate
students Hui Huang and Talon Trecek, and Laura Arthur, who rotated in our lab and
helped with my project.  Similarly, I’d like to thank Roberto Tapia, who worked with me
vii
for a year when everything seemed like it wasn’t working, but he stayed positive and
helped me do the same.  His help was invaluable.
I’d also like to thank the rest of my friends, fellow graduate students, and the many
members of the BRIGHT and ICCE institutes who were a constant source of help and
reagents. Thank you also to the many other professors, post-docs, staff members, and
students who helped me in countless big and small ways, both in science and in life.
Thank you to my many teachers over the years, both formal and informal. I am grateful
from funding from NIH Cellular Biochemical and Molecular Sciences Pre-doctoral
Training Grant T32 GM007067 and NIH F31 CA189669.
I’d like to thank my parents, who taught me the importance of education and made it
possible for me to get a great one.  Specifically, I’d like to thank my mom, Jan Flanagan,
the only scientist I knew growing up, for being a role model and giving me—whether
through genes or environment—an interest in science and biology.  I’d like to thank my
dad, Jim Flanagan, for teaching me the value of working hard and working well, and of
making time for things that are important.  Thank you to my brothers and their families
for being role models, a welcome distraction from science, for intentionally
misunderstanding what I do in lab, and for celebrating my victories and sometimes
letting me forget my failures.  I’d also like to thank my parents-in-law and the entire
Berlage family for making me one of their own and supporting and helping me along the
way.
viii
Finally, I’d like to thank my wife, Laura, and my daughter, Clare.  Laura followed me to
St. Louis and has been my biggest supporter in graduate school and life.  She put up
with weekends in lab and cells that always needed to be split. She endured pushed
back deadlines, delayed dinner times, and patiently avoided asking when I would
graduate. She encouraged me and motivated me.  Clare inspired me, cheered me, and
reminded me that there are more important things than failed experiments.
Kevin C. Flanagan
Washington University in St. Louis
May 2017
ix
ABSTRACT OF THE DISSERTATION
Regulation of the pro-tumorigenic senescence-associated secretory phenotype
by
Kevin Colin Flanagan
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, April 2017
Dr. Sheila A. Stewart, Chair
Tumorigenesis results from the convergence of cell autonomous mutations and
corresponding stromal changes that promote tumor cell growth.  Mutations and stromal
changes both accumulate with age and together account for the dramatic increase in
cancer incidence with age.  One change that occurs with age is the accumulation of
stromal senescent cells. Senescent stromal cells secrete pro-tumorigenic factors
collectively termed the senescence-associated secretory phenotype (SASP).  The
SASP impacts every stage of tumorigenesis and is a promising therapeutic target.  As
such, it is important to understand how the SASP is regulated.
Many but not all SASP factors are regulated transcriptionally by NF-kB and its upstream
activator p38MAPK.  However, many pro-tumorigenic SASP factors, including
osteopontin (OPN), are not dependent on NF-κB or other canonical SASP regulators
such as ATM, leaving the regulation of these factors an open question.  Here, I report
that the transcription factor c-Myb regulates OPN, IL-6, IL-8 and other SASP factors.
xThe regulation of OPN is direct as c-Myb binds to the OPN promoter in senescent cells,
and this binding is required for promoter activation. Further, OPN is also regulated by
the known SASP regulator C/EBPβ.  In response to senescence, the full-length
activating C/EBPβ isoform LAP2 increases binding to the OPN, IL-6, and IL-8
promoters. Using a microarray and RNAi approach, we identified 57 additional putative
c-Myb-dependent SASP factors and 125 additional putative C/EBPβ SASP factors.
There is a high degree of overlap between c-Myb- and C/EBPβ-dependent factors. The
importance of both c-Myb and C/EBPβ is underscored by our finding that the depletion
of either factor reduces the ability of senescent fibroblasts to promote the growth of
preneoplastic epithelial cells.
Furthermore, I describe a post-transcriptional SASP mRNA stability regulator pathway.
This pathway is dependent on p38MAPK, but is distinct from p38MAPK’s role in NF-κB
transcription of SASP factors.  In fully senescent fibroblasts, p38MAPK regulates the
removal of mRNA-destabilizing protein AUF1 from the 3’-UTRs of numerous SASP
factor mRNAs, resulting in increased mRNA stability.  Given p38MAPK’s role in both
transcriptional and post-transcriptional regulation of the SASP, we tested the ability of
p38MAPK inhibitors to inhibit tumor growth.  Treatment of mice with an orally-
administered p38MAPK inhibitor significantly decreased tumor growth in senescent
fibroblast-supported xenograft models.  Importantly, p38MAPK inhibition acts upon the
microenvironment by removing stromal support of tumor growth.  Interestingly,
p38MAPK inhibition also inhibits the tumor promoting activities of cancer-associated
fibroblasts (CAFs).  CAFs have a secretory profile similar to senescent fibroblasts.  This
xi
work indicates that p38MAPK inhibition is a viable therapeutic for targeting both
senescent fibroblast and CAF stromal support of tumor cell growth.
1CHAPTER 1
Introduction and Significance
2Cellular senescence is a stress-response
Eukaryotic cells have evolved numerous strategies to overcome the insults and stresses
presented by the environment, repeated DNA replication and cell division, and DNA
mutations.  In multicellular organisms, it is critical to maintain functional tissues and
avoid proliferation of dysfunctional cells.  One method organisms have developed is the
induction of senescence.  Senescence, a permanent cell cycle arrest characterized by a
number of phenotypic changes, was first observed in vitro by Leonard Hayflick in 1965
(1).  Although it had previously been believed that mammalian cells could undergo an
unlimited number of cell divisions in vitro, Hayflick demonstrated that normal human
cells will no longer divide after approximately 40-60 divisions.  This limit is known as the
Hayflick limit and was the first description of cellular senescence. Although it was
widely assumed to be an artifact of tissue culture, it is now known that senescence
occurs both in vitro and in vivo, where it plays important roles. It was later shown that
the senescence Hayflick observed was induced by the shortening and eventual loss of
telomeric DNA (2).  More recent findings indicate that it is the loss of telomeric integrity,
and not telomeric shortening per se, that can drive entrance into senescence. In the
decades since it was first described, significant progress has been made in
understanding the phenotypes associated with senescence, the mechanisms driving
senescence, and the physiological and pathological roles of senescence.
In addition to telomere shortening or dysfunction, cellular senescence can be caused by
DNA double strand breaks, epigenetic alterations to chromatin, oxidative or metabolic
stress, tumor suppressor expression, and oncogene activation (3). When it occurs in
3incipient tumor cells, senescence is a potent anti-tumor mechanism which prevents
continued proliferation of cells with dysfunctional telomeres, extensive and persistent
DNA damage, oncogene activation, or other stresses which could lead to the formation
of tumors.  Interestingly, senescent cells are resistant to apoptosis, another important
tumor suppressive mechanism (4).  Although senescent cells do not divide, they remain
metabolically active and generally adapt a number of senescence-associated
phenotypes, including a flattened morphology, the presence of heterochromatic foci
(SAHFs), positive senescence-associated β-galactosidase staining, and an altered gene
expression and secretion profile termed the senescence-associated secretory
phenotype (SASP; ref. 8–12).
Although many cellular insults can induce senescence, they all converge on two related
pathways which activate the senescence program.  The tumor suppressors p53 and Rb
are both critical for the induction of senescence in most contexts. p53 is commonly
activated in response to DNA damage, excessive reactive oxygen species (ROS), or
activation of oncogenes such as Ras (9).  In turn, p53 activates p21Cip1, a cyclin-
dependent kinase inhibitor, which arrests the cell cycle (10).  Likewise, Rb, which
prevents progression of the cell cycle from G1 to S, is activated by p16 INK4A in response
to a variety of stresses.  Although p16 is not required for the induction of senescence,
p16 is often used as a marker of senescence, particularly in vivo.  While the p53 and Rb
pathways are interconnected, they act mostly independently to induce senescence and,
in the right context, activation of either pathway alone is sufficient to induce
senescence.
4Senescence plays important physiological and pathological roles
While senescence was first described and characterized in vitro, it is now known to
occur in vivo, where it impacts a diverse and growing list of physiological processes and
is implicated in multiple pathologies.  For instance, senescent cells are important for
normal mammalian development, including in the apical ectodermal ridge and structures
in the ear (11, 12).  A recent report also indicates that senescence can also act as an
antiviral mechanism (13). Further, clearance of senescent cells from mice inhibits
wound repair (14).  Interestingly, while short-lived senescent cells seem to be important
for wound healing, the persistent presence and accumulation of senescent cells can
contribute to tissue dysfunction.  While many senescent cells are rapidly cleared by the
immune system, senescent cells do accumulate with age (15–17), potentially altering
the microenvironment and contributing to many age-related diseases.
Indeed, work using various senescent cell clearing models in mice has indicated that
clearance of senescent cells reverses multiple aging phenotypes.  Using a transgenic
mouse model which activates a suicide gene in response to AP20187 (AP) treatment in
p16INK4A-expressing cells (INK-ATTAC), Baker et al. selectively removed p16-positive
senescent cells from young and old mice (18).  Treatment of progeroid mice with AP
starting at weaning resulted in significantly delayed aging phenotypes such as
sarcopenia, cataracts, and loss of adipose tissue.  Further, starting AP treatment at five
months of age in the same progeroid mice significantly increased adipose tissue, the
size of muscle fibers, and resulted in increased treadmill exercise test performance at
5ten months, indicating that elimination of senescence cells in this setting can not only
delay but also rescue aging phenotypes associated with this mouse model.
Similar results were obtained in naturally aged mice (19).  Indeed, clearance of
p16INK4A-positive cells resulted in increased lifespan and healthspan as measured by
numerous metrics including delayed cataracts and increased activity and exploratory
behavior. These studies and others indicate that senescent cells play an important role
in aging and can contribute to diverse aging phenotypes including cardiac aging,
glomerulosclerosis, decreased motor activity, cancer, and overall lifespan (20, 21).
Further, not only can elimination of senescent cells inhibit or delay aging phenotypes, it
can also reverse some aging phenotypes, making senescent cells an appealing
therapeutic target.
Indeed, in the last two years there has been increasing research on “senolytic” drugs,
those that target and selectively kill senescent cells (20–23).  Senescent cells are
resistant to apoptosis (4).  Most senolytic drugs sensitize senescent cells to apoptosis
by targeting apoptotic proteins such as Bcl-2 family members (22).  Treatment with two
senolytic drugs which target Bcl-2 proteins can improve cardiovascular function and
reduce aortic calcification, phenocopying improvements seen in genetic models of
senescent clearance (23).  Likewise, a recent report indicates FOXO4 is elevated in
senescent cells and is required for senescent cell resistance to apoptosis (20).
Treatment with a peptide which blocked interaction between FOXO4 and p53 resulted in
selective apoptosis of senescent cells.  Treatment with this peptide improved multiple
6measures of health in both progeroid and naturally aged mice, including restoring hair
growth and improving renal function.  Further, treatment reduced chemotherapy side-
effects such as liver damage.  Together with models of genetic clearance of senescent
cells, research using senolytic drugs has demonstrated that in addition to the important
physiological and anti-tumor roles of senescent cells, senescent cells contribute to
numerous aging phenotypes and pathologies.  Further, while senolytic drugs are far
from use in the clinic, recent work has demonstrated that it is possible to selectively
target senescent cells and that senolytic drugs hold great promise in the treatment of
many diseases.
Therefore, it is important to understand the mechanisms by which senescent cells
promote the varied aging phenotypes described.  Senescent cells may contribute to
aging and tissue function decline simply by taking the place of a healthy, proliferating
cell, particularly progenitor and stem cells (24).  However, while the mere accumulation
of non-dividing cells may play a role, there is significant evidence that senescent cells
play an active role in many disease states.  In fact, senescent cells have an altered
secretory profile known as the senescence-associate secretory phenotype (SASP; ref
8).  The SASP can alter local tissue homeostasis and promote disease states through a
diverse set of mechanisms (5–8, 17, 24–26).
The senescence-associated secretory phenotype is pro-tumorigenic
The SASP consists of numerous inflammatory, mitogenic, and ECM-remodeling factors
that are upregulated at the mRNA and protein levels and can promote tumor initiation
7and development (6, 27, 28).  The specific factors which are upregulated depends on
the cell and tissue type as well as the means of senescence induction (29, 30).
However, many “canonical” SASP factors, such as IL-6 and IL-8, are commonly
upregulated in many contexts.  Taken together, the known functions of SASP factors
can impact every stage of tumorigenesis and progression, including tumor initiation,
expansion, vascularization, local invasion, and metastasis (6, 7, 24, 25, 28).
Senescence is a potent tumor suppressive mechanism and yet, through the SASP, is
also potently tumor promoting.  This apparent paradox is explained by the differing
effect of senescence in a cell autonomous versus a cell non-autonomous setting.
Senescence does prevent cancer initiation in incipient tumor cells that senesce.
However, when they arise in the stromal compartment senescent cells can promote
tumor development in other nearby cells.  Indeed, work over the last decade has
demonstrated the importance of the stroma in tumorigenesis (31).
Traditionally, cancer has been thought of as a disease of a single, typically epithelial,
cell which accumulates mutations and begins to proliferate uncontrollably.  However,
more recent work has indicated that a carcinoma arises and progresses through a
complex process of communication between the incipient tumor cell and its
microenvironment, which consists of stromal cells such as fibroblasts, immune cells,
vasculature, the extracellular matrix, and other epithelial cells.  Furthermore,
communication between the incipient tumor cell and the microenvironment is
bidirectional (32). Clearly nascent tumors can shape their microenvironment in many
8ways such as inhibiting the immune response and promoting vascularization.  However,
stromal cells also direct the evolution of nascent tumors.  For instance, when non-tumor
forming pre-neoplastic epithelial cells are injected into a mouse either alone or with
normal fibroblasts, they are unable to establish tumors.  However, if the same pre-
neoplastic epithelial cells are coinjected with tumor-educated cancer-associated
fibroblasts (CAFs), which themselves are not cancerous, the CAFs will promote the
formation of tumors by the pre-neoplastic cells (33).  This work indicates that the stroma
plays an active role and can drive epithelial cells to form tumor cells when they
otherwise would not.
Interestingly, fibroblasts can also restrain tumor growth.  Coinjection of tumor-forming
epithelial cells with normal fibroblasts can inhibit tumor formation. Perhaps even more
strikingly, injection of blastocysts with teratocarcinoma cells will form mosaic mice
which, despite containing teratocarcinoma cells, are tumor free (34). Thus, stromal
fibroblasts can either promote or repress tumor initiation and growth, indicating that the
stroma and tumor microenvironment plays an important role in cancer biology.  Indeed,
senescent stromal cells also promote tumorigenesis.  Coinjection of senescent
fibroblasts with pre-neoplastic epithelial cells will drive increased tumor initiation and
growth in a similar manner to coinjection of CAFs (7, 8, 28).  So while senescence can
prevent tumor formation in a cell autonomous manner, this mechanism comes at a cost
to the organism as senescent stromal cells can promote the development of tumors in
nearby tissue.
9The evolution of a senescence mechanism which provides a benefit to the organism but
is also detrimental can be explained by the hypothesis of antagonistic pleiotropy.
Antagonistic pleiotropy suggests that natural selection favors traits that increase fitness
during reproductive years even if they come at a cost later in life.  Cancer is a disease
of aging, with the vast majority of cases occurring after peak reproductive years (35).
Senescence helps prevent the formation of tumors in younger individuals, allowing them
to have a healthy reproductive lifespan.  However, as the individual ages senescent
cells accumulate in their tissues and begin to affect physiology, including promoting
tumorigenesis (17, 36). Because this cost is delayed until after reproduction it is not
strongly selected against during evolution. Thus, cancer is a disease of the aged in part
because senescence both prevents cancer formation in young individuals and can
promote it cell non-autonomously in aged individuals.
Senescence, via the SASP, can promote cancer via multiple mechanisms. For
instance, senescent fibroblasts can directly promote cell growth as well as promote
EMT, an important step in metastasis (7, 28). In addition, senescent fibroblasts can
induce local immune invasion, resulting in increased myeloid cell populations and
immunosuppression (17). This occurs even in the absence of a tumor and creates a
tumor-permissive environment. Senescence can also promote migration and invasion
of tumor cells (8, 37). This work and more, along with studies demonstrating that
clearance of senescent cells can positively impact multiple aging phenotypes, suggests
that targeting senescent stromal cells via the SASP may be a powerful therapeutic
opportunity.
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The SASP is regulated by multiple pathways
In order to target the SASP therapeutically, it is vital to understand how it is regulated.
The regulation of SASP induction is complex and incompletely understood.  One potent
inducer of senescence is persistent DNA-damage and the subsequent DNA-damage
response (DDR) signaling.  ATM is a central mediator of the DDR and is required for the
induction of many SASP factors, including IL-6 and IL-8 (38).  However, many SASP
factors do not require ATM for their induction.  For instance, the induction of
Osteopontin (OPN) does not require ATM activity (39).  Many SASP factors are
transcriptionally activated by NF-κB and C/EBPβ (39–42).  NF-κB seems to act in the
same pathway as ATM, as ATM depletion decreases NF-κB activity in senescent cells
(40).  As with ATM, a subset of SASP factors, including OPN, are NF-κB-independent
(39).  NF-κB is also downstream of another important SASP regulator, the stress-
induced kinase p38MAPK (40).  Depletion of p38MAPK prevents the induction of many
SASP factors, and constitutive activation of p38MAPK signaling results in SASP
induction even in the absence of additional senescence cues.  Further, ATM is not
required for p38MAPK activation or activation of the SASP by p38MAPK, suggesting
that ATM and p38MAPK act in parallel pathways to activate NF-κB signaling.  While
p38MAPK induces many SASP factors, at the protein level only 25 of 37 SASP factors
studied required p38MAPK signaling, suggesting that, like ATM and NF-κB, it is far from
a universal SASP regulator (40). Many of the SASP factors regulated by ATM,
p38MAPK, and NF-κB are inflammatory genes, while many matrix remodeling proteins
and growth factors are independent of these pathways.
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NF-κB, while not a universal SASP regulator, is a key regulator of the SASP.  The
regulation of NF-κB in senescent cells is complex, however.  In addition to the roles
ATM and p38MAPK play in activating NF-κB in response to senescence, feedback
loops also modulate NF-κB activity.  In response to senescence, NF-κB promotes
transcription of SASP factors such as IL-6 and IL-1α.  These factors are important for
reinforcing senescence and promoting the SASP (41, 43).  IL-1α in particular is
upregulated by senescent cells and further promotes NF-κB and C/EBPβ activity,
leading to further activation of the SASP (43).  This positive feedback loop is mediated
in part by mTOR, which promotes IL-1α translation (44).  Inhibition of mTOR suppresses
the upregulation of many NF-κB-dependent SASP factors.  Thus, the NF-κB-dependent
arm of the SASP is regulated by many factors at numerous levels.  Still, NF-κB-
dependent SASP factors represent only a subset of all SASP factors.  For instance, only
35% of studied factors are mTOR-dependent, all of them also being NF-κB-dependent
(44).  Thus, there is considerable need to understand how NF-κB-independent SASP
factors are regulated.
OPN is protumorigenic and distinctively regulated
The lack of broad SASP regulators on which nearly all SASP factors are dependent
suggests that the SASP is not regulated by a single program but rather many
overlapping regulatory mechanisms. This notion is further supported by the diversity of
specific SASP factors which are conditionally upregulated depending on the cell type
and senescence inducer.  One such factor is osteopontin (OPN), a protumorigenic
protein which has numerous physiological and pathological roles, including regulating
12
bone turnover, cell adhesion and migration, and inflammation (45–48).  OPN is a
secreted matrix protein that may anchor osteoclasts to the matrix (47), is upregulated in
response to wounds, acts to recruit immune cells, can suppress apoptosis, and is
upregulated in a number of cancer types (46, 49–52).  OPN is also robustly upregulated
in response to stress-induced, replicative, and oncogene-induced senescence in human
cells (28).
Previous work in our lab demonstrated that in a two-stage skin carcinogenesis model,
stromal cells stained positive for SA-βgal and p16INK4A prior to the appearance of
hyperplasia.  This work further demonstrates that senescent cells can play a role in
promoting carcinogenesis and are not simply a by-product of tumor formation.
Importantly, stromal cells staining positive for p16INK4A also stained positive for OPN,
indicating that in vivo senescent mouse skin cells express OPN and that it may be
playing a role in promoting tumorigenesis (28).  Further, human AK and SCC skin
lesions displayed coincident stroma cell staining for p16INK4A and OPN, suggesting that
in human pre-neoplasias and neoplasias, stromal senescent cells express OPN and
that OPN may be important in human tumorigenesis (53).  Using in vitro cocultures
assays and in vivo xenografts, our lab demonstrated that knocking down OPN in BJ
fibroblasts eliminated the ability for senescent fibroblasts to promote the growth of
preneoplastic HaCaT skin epithelial cells.  Thus, OPN is necessary for senescent-
fibroblast promoted preneoplastic cell growth in this context.
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Additionally, treatment of pre-neoplastic HaCaT or N.p.c.T epithelial cells with
recombinant human OPN (rhOPN) is sufficient to induced growth in vitro in the absence
of senescent fibroblasts (28).  In this context, rhOPN acts to promote cell growth via the
MAPK pathway via the CD44 receptor (53). However, the growth induction using rhOPN
did not recapitulate the magnitude of growth induction by senescent fibroblasts,
suggesting that either additional factors secreted by senescent cells also play important
roles, or that, given OPN is a highly modified protein, the rhOPN lacked some important
post-translational modifications to achieve maximal growth promotion.  These data
together demonstrate that, at least in this skin carcinoma context, OPN is an important
SASP factor for the promotion of pre-neoplastic cell growth by senescent cells.  OPN is
an extracellular matrix-associated protein and can promote cell migration (48).  In fact,
its expression correlates with tumor cell migration and invasion in squamous cell
carcinoma (54), raising the possibility that senescent fibroblast-derived OPN may
promote tumor invasion and metastasis in addition to cell proliferation.  However, this
possibility remains an untested area for future study.
Given senescent-derived OPN’s ability to promote tumorigenesis, it is important to
understand how OPN is regulated in senescent cells.  However, the regulation of OPN
in response to senescence is not understood.  SASP regulators ATM and NF-κB are not
required for OPN induction in response to senescence (39). Other SASP regulators,
such as C/EBPβ, have not been studied in conjunction with OPN.  Indeed, there are no
known regulators of OPN in response to senescence.
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The transcription factor C/EBPβ has three isoforms and regulates the SASP
One possible regulator of OPN is the transcription factor C/EBPβ.  C/EBPβ belongs to
the C/EBP family of transcription factors which also includes C/EBPα, C/EBPγ, C/EBPδ,
C/EBPε, and C/EBPζ, each representing a distinct gene locus (55, 56).  C/EBP
transcription factors bind to DNA as a dimer and can do so as homodimers or as
heterodimers consisting of two different C/EBP isoforms (57).  C/EBPβ itself consists of
three different isoforms translated from the same mRNA using alternative translation
start sites.  Two of the isoforms, LAP and LAP2 (Liver Activating Protein 1 and 2,
respectively), contain the transactivation domain and activate transcription when they
bind to promoters (55, 56).  Although there is evidence for unique roles between LAP
and LAP2 and distinct molecular targets, little is known about these differences nor their
functional importance.  The third isoform, LIP (Liver Inhibitory Protein), lacks the
transactivation domain and acts in a dominant negative fashion to inhibit the activity of
LAP and LAP2 (58).  LIP can bind both to DNA as well as to the LAP and LAP2
isoforms.  A C/EBPβ heterodimer consisting of LIP and one of the activating isoforms is
unable to activate transcription (58). In addition to its known ability to regulate numerous
genes such as cytokines as well as SASP factors specifically, C/EBPβ has been shown
to regulate OPN in liposarcomas and lung cancer cells (59, 60).  In addition to
dimerizing with itself or other C/EBP family members, C/EBPβ also frequently interacts
with other transcription factors, including the proto-oncogene c-Myb (61).  With c-Myb,
C/EBPβ coactivates transcription of several genes, including mim-1 and ChAT (62–64).
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The transcription factor c-Myb is a proto-oncogene
One possible regulator of SASP factors is the transcription factor c-Myb.  C-Myb is a
proto-oncogene and is the mammalian homologue of the Avian myeloblastosis virus
(AMV) v-myb oncogene (65, 66).  V-myb is a 45 kD truncation of c-Myb and causes
leukemia in various bird species (65, 67).  Normal, endogenous, cellular c-Myb is highly
conserved in animals, and Myb family members and homologues are present in a wide
variety of species, including plants (68, 69).
Human c-Myb is a 75 kD DNA-binding protein consisting of three major domains: a
DNA-binding domain (DBD), a negative regulatory domain (NRD), and a transactivation
domain (TAD; ref. 65).  C-Myb has multiple isoforms due to alternative splicing and is
subject to numerous post-translational modifications, including phosphorylation and
sumoylation, which can regulate its localization and activity (70–74).  In addition, c-Myb
cooperates and interacts with many other transcription factors to regulate transcription
(75).
In mammals, c-Myb is best studied in hematopoietic development (76).  c-Myb is critical
for hematopoietic differentiation, including that of B cells and T cells (77–81).
Additionally, it plays important roles in proliferation and expansion of certain cell
lineages and low expression results in a myeloproliferative phenotype (82).  Importantly,
the role of c-Myb varies among different cell types, with many different transcriptional
targets depending on context (83).  More recent work has shown that c-Myb has roles in
16
differentiation, proliferation, and stem cell maintenance in settings such as colon crypt
epithelial cells (84–86), neural progenitors and stem cells (87), and melanocytes (88).
Additionally, c-Myb is a known regulator of OPN in hepatocellular carcinoma and
melanoma models (89, 90).  However, c-Myb is poorly characterized in fibroblasts and
has not been studied in mammalian cell senescence.  C-Myb was first characterized as
being expressed and having roles in fibroblasts in 1997, where it was shown to regulate
cell-cycle progression and intracellular calcium levels (91).  C-Myb has not been studied
as a regulator of OPN in fibroblasts.
As a transcription factor, c-Myb binds to DNA as monomer (92).  In a manner somewhat
unusual for a transcription factor, however, c-Myb often binds to promoter regions
without activating transcription (93).  Instead, it may serve to prime promoters for co-
activation by other transcription factors (94).  Supporting this idea, c-Myb is known to
interact with a number of other transcription factors including CBP, p300 and, as
mentioned, C/EBPβ (61, 95).  Given their previously reported abilities to regulate OPN
in other contexts, I hypothesized that c-Myb and C/EBPβ regulate OPN in response to
senescence.  In addition, I hypothesized that other SASP factors may also be activated
by c-Myb and C/EBP in response to senescence.
This thesis work focuses on better understanding the regulation of the SASP.  I
investigate the transcriptional regulation of SASP factors including OPN by the novel
SASP regulator c-Myb.  In addition, I describe a post-transcriptional regulatory role for
17
p38MAPK.  Further, I investigate the potential efficacy of using drugs that target the
p38MAPK pathway as a cancer therapy.  This work expands the understanding of
SASP regulation and advances our ability to understand and combat the contributions
of the SASP to diseases of aging.
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CHAPTER 2
c-Myb and C/EBPβ regulate OPN and other senescence-associated secretory
phenotype factors
Kevin C. Flanagan, Elise Alspach, Ermira Pazolli, Shankar Parajuli, Laura L. Arthur,
Roberto Tapia, and Sheila A. Stewart
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INTRODUCTION
Age is a major risk factor in the development of cancer (1).  In addition to the
accumulation of epithelial cell mutations, age-dependent changes in the stromal
compartment play an important role in tumor promotion (2–7).  One of these changes is
the accumulation of senescent stromal cells that possess the ability to stimulate
preneoplastic and neoplastic cell growth. First described as an in vitro phenomenon
caused by repeated cell divisions, senescence can also be caused by a number of
genotoxic stresses including telomere shortening or dysfunction, DNA double strand
breaks, oxidative stress, tumor suppressor expression, and oncogene activation (8).
Senescent cells are associated with a flattened morphology, the presence of
heterochromatic foci (SAHFs), positive senescence-associated β-galactosidase
staining, and an altered gene expression and secretion profile termed the senescence-
associated secretory phenotype (SASP; ref. 8–12).  Significantly, senescence is now
known to occur both in vitro and in vivo (9, 13) where it impacts a diverse number of
biologic processes including cancer.
Senescence acts as a potent tumor suppressive mechanism in a cell autonomous
setting by preventing the proliferation of cells with activated oncogenes or excessive
DNA damage.  However, as individuals age, senescent cells accumulate within tissues
where they are postulated to contribute to aging phenotypes (9, 10).  Aged mice cleared
of p16Ink4a-positive senescent cells have reduced incidences of several age-related
pathologies (2, 14). Further, senolytic drugs that target senescent cells can ameliorate
many age-related maladies, underscoring the importance of these cells in age related
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diseases (15–17). Additionally, the largest risk factor for cancer is age, and there is
significant evidence that accumulating senescent cells paradoxically contribute to
cancer development and progression in a cell non-autonomous fashion.  As with other
age-related diseases, elimination of senescent cells reduces spontaneous tumor rates
in naturally aged mice (14, 17).  The SASP can promote growth and transformation of
epithelial cells in numerous models, suggesting that secretion of the SASP by
accumulating senescent cells may contribute to age-related tumorigenesis (3, 4, 7, 11,
12, 18–20).
The SASP consists of numerous secreted factors including cytokines, mitogens, and
extracellular matrix remodelers that are upregulated at the mRNA and protein levels (7,
12). The regulation of SASP expression is complex and incompletely understood but
recent work has revealed that both the cell type and senescence inducer can
significantly impact the mechanisms that regulate SASP expression as well as the
specific SASP factors expressed (21). The expression of many factors, including the
canonical SASP factors IL-6 and IL-8, requires p38MAPK, ATM, and NF-κB for
transcriptional activation (5, 8, 12).  Additionally, p38MAPK regulates many SASP
factors via post-transcriptional stabilization of their mRNA (Chapter 3, ref. 6).  However,
not all SASP factors are regulated by these same pathways.  For instance, while
p38MAPK is an important regulator of the SASP, one study found that it regulated only
25 of 37 factors studied at the protein level while we previously reported that it regulates
only 50 of 248 factors at the mRNA level in our model (5, 6).
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One such factor is osteopontin (OPN), a pro-tumorigenic protein which has numerous
physiological and pathological roles, including regulating bone turnover, cell adhesion
and migration, and inflammation (22–25). OPN is a secreted matrix protein that is
upregulated in response to wounds, acts to recruit immune cells, can suppress
apoptosis, and is upregulated and diagnostically relevant in a number of cancer types
(24, 26–28).  OPN is also robustly upregulated in response to senescence.  Previously
we showed that senescent BJ skin fibroblasts lose the ability to promote preneoplastic
cell growth when they are depleted of OPN.  Furthermore, recombinant OPN induces
preneoplastic cell growth in the absence of senescent cells (7, 29).  While the
importance of senescent fibroblast-derived OPN is underscored by its ability to promote
preneoplastic cell growth, the regulation of OPN in response to senescence is not
understood.  SASP regulators ATM and NF-κB are not required for OPN induction in
response to senescence (30).  Other SASP regulators, such as C/EBPβ, have not been
studied in conjunction with OPN.  Indeed, there are no known regulators of OPN in
response to senescence.  Because of senescent-derived OPN’s ability to promote
preneoplastic cell proliferation, it is important to understand how OPN is regulated in
this context.  Additionally, elucidating the regulation of OPN may provide insights into
the regulation of other SASP factors that are regulated in a similar manner.
To identify regulators of OPN, we used an OPN promoter reporter to identify a
senescence response element (SRE) that was required for activation of the OPN
promoter in response to senescence.  Using Transfac® to analyze the SRE for
transcription factor binding motifs, we identified a number of putative regulators of OPN
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in senescence, including C/EBPβ and c-Myb.  C/EBPβ is a transcription factor known to
regulate IL-6 and IL-8 in response to senescence (31).  Likewise, it has been shown to
regulate OPN in a lung cancer cell line (32).  c-Myb is a proto-oncogene important for
hematopoietic development (33).  Additionally, c-Myb is a known regulator of OPN in
hepatocellular carcinoma and melanoma models (24, 34).  However, c-Myb is poorly
characterized in fibroblasts and has not been studied in mammalian cell senescence.
Further, c-Myb and C/EBPβ can collaborate to activate transcription of a number of
genes, including mim-1 and ChAT (35–37). Therefore, we hypothesized that c-Myb and
C/EBPβ regulate OPN and other SASP factors.
METHODS
Cell lines and treatments
Human foreskin BJ fibroblasts and 293T cells were cultured as previously described (7).
HaCAT preneoplastic keratinocyte cells stably expressing click beetle red (CBR)
luciferase (HaCAT-CBR) and HEK 293T cells were grown in DMEM containing 10%
heat-inactivated FBS and 1% penicillin/streptomycin (Sigma; ref. 7). All cells were
cultured at 37°C in 5% carbon dioxide and 5% oxygen.
Cells were treated with 0.1 U/mL bleomycin sulfate (Sigma) for 24 hours.  Cell pellets
were collected 96 hours after the start of bleomycin treatment and RNA was isolated
using TRI Reagent (Life Technologies) and Ambion RNA Isolation kit (ThermoFisher).
Plasmids
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OPN promoter luciferase constructs consisted of a fragment of the OPN promoter
driving expression of luciferase in the pGL3 vector (38).  Fragments used were OPN80
(nucleotide [nt] -80 to nt +86), OPN108 (nt -108 to nt +86), OPN135 (nt -135 to nt +86),
OPN190 (nt -190 to nt +86), and OPN400 (nt -400 to nt +86). The nt reported
correspond to those upstream (-) or downstream (+) of the transcriptional start site.  The
OPN-LUC promoter constructs were a gift from the Paul C. Kuo Lab (38). OPN190-
LUC mutant c-Myb binding site was created using QuikChange II Site-Directed
Mutagenesis (Agilent) and by following manufacturer’s protocol.  The c-Myb binding site
was changed from 5’-ttaactgtagatt-3’ to 5’-ttgctagtagact-3’. pCMV-FLAG-LAP2
(Addgene plasmid #15738) and pBabe-puro LIP  (Addgene plasmid #15713) were gifts
from Joan Massague (39). pCDNA3.1-Myb was a gift of Dr. Robert Rosenberg. pWZL
hygro H-Ras V12 was a gift from Scott Lowe (Addgene plasmid # 18749, ref. 37).
shMyb_2 (pSIREN-RetroQ-MYB-shRNA) was a gift from Judy Lieberman (Addgene
plasmid # 25790; ref. 37). All other shRNA constructs were obtained from the
Children’s Discovery Institute’s viral vector-based RNAi core at Washington University
in St. Louis and were supplied in the pLKO.1-puro backbone.  The sequences are as
follows: shLUC (5’-TCACAGAATCGTCGTATGCAG-3’), shCEBP_1 (5’-
CGACTTCCTCTCCGACCTCTT-3’), shCEBP_2 (5’-GCACAGCGACGAGTACAAGAT-
3’), shMYB_2 (5’-CCAGATTGTAAATGCTCATTT-3’).
SA-βgal
Senescence-associated-β-galactosidase staining was carried out as previously
described (7).
33
Growth Assay
50,000 untreated or bleomycin-treated BJ fibroblasts expressing the indicated short
hairpins were plated 96 hours after the start of treatment as previously described.  Cell
number was counted daily for four days using a hemocytometer.  Significance was
determined using  a 2-way ANOVA with Bonferroni post-test.
Western Blot
Cell pellets were lysed in buffer containing 50 mM Tris pH 8.0, 5 mM EDTA, 0.5% NP-
40, and 100 mM sodium chloride for 20 minutes at 4°C. Protein concentration was
quantified using the Bradford Protein Assay (Bio-Rad). Membranes were blocked for
one hour in 5% milk in TBS-T. The primary antibodies used were mouse monoclonal
anti-FLAG M2 (Sigma; catalog number F1804) diluted 1:1000; rabbit polyclonal anti-
C/EBPβ (Santa Cruz sc-150) diluted 1:2500; rabbit polyclonal anti-c-Myb rabbit
polyclonal (Santa Cruz sc-517) diluted 1:250; and anti-γ-actin (Novus; catalog number
NB600-533) diluted 1:5000. All secondary antibodies from the appropriate species
were horseradish peroxidase–conjugated (The Jackson Laboratory) and diluted at
1:10,000.  All antibodies were diluted in 2% BSA (Sigma-Aldrich) in TBS-T or 1% milk in
TBS-T.
Viral transduction
Viral transduction was performed as previously described (7). All constructs were stably
expressed using viral transduction unless otherwise noted.
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Luciferase Reporter Assay
BJ fibroblasts were transiently co-transfected with pGL3-Renilla and pGL3-OPN
constructs using Lipofectamine 2000 (Thermo Fisher Scientific) and promoter activity
was determined using Promega Dual Luciferase Reporter Assay (Promega) by following
manufacturer’s protocol.
Chromatin Immunoprecipitation
Cells were transiently transfected with pcDNA-c-Myb WT (Myb), pGL3-OPN190
(OPN190), pGL3-OPN190 mutant c-Myb binding site (OPN190 Mut), or pCMV-Flag-
LAP2 in 15 cm plates using 7 µg DNA and the TransIT® LT1 Reagent transfection
system (Mirus).  Cells were fixed 48 hours later using 1% formaldehyde in PBS for 20
minutes.  Fixation was quenched with 125 mM glycine for 5 minutes with gentle rotation,
cells were washed with PBS and collected by scraping and centrifugation at 200xg for 5
minutes at 4°C.  Cells were lysed in 2 mL lysis buffer (1% SDS, 10 mM EDTA, 50 mM
Tris pH 8.1) containing protease inhibitors (pepstatin, 1 μg/mL; aprotinin, 1 μg/mL;
leupeptin, 1 μg/mL; PMSF, 100 μM) for 15 minutes.  The lysate was sonicated at 50
Amps with 30 s on, 30 s off for 6 rounds to achieve DNA fragments approximately 200-
500 bp in length as measured by electrophoresis.  One mg protein was used for each
immunoprecipitation.  Lysate was diluted fivefold into ChIP dilution buffer (0.01% SDS,
1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1, 167 mM NaCl) and
incubated at 4°C overnight with 5 μg appropriate antibody with vertical rotation.
Antibodies used: anti-Myb (Santa Cruz sc-517); anti-C/EBPβ (Santa Cruz sc-150);
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Rabbit IgG (Cell Signaling 2729); anti-Flag M2 (Sigma F1804); mouse IgG1 (for Flag
ChIPs, Cell Signaling 5415).
Quantitative PCR
cDNA synthesis and quantitative PCR was performed using manufacturer’s instructions
(SYBR Green, Life Technologies and Taqman, Applied Biosystems).  Primers used:
GAPDH (F: GCATGGCCTTCGGTGTCC, R: AATGCCAGCCCCAGCGTCAAA), IL-6 (F:
ACATCCTCGACGGCATCTCA, R: TCACCAGGCAAGTCTCCTCA), IL-8 (F:
GCTCTGTGTGAAGGTGCAGT, R: TGCACCCAGTTTTCCTTGGG), OPN (F:
TTGCAGCCTTCTCAGCCAA, R: AAGCAAATCACTGCAATTCTC), c-Myb (IDT
PrimeTime® Std qPCR assay #Hs.PT.58.264008, Probe: 5’-56-
FAM/CCTTCCGAC/ZEN/GCATTGTAGAATTCCAGT/3IABkFQ/-3’, F: 5’-
CTCCTGCAGATAACCTTCCTG-3’, R: 5’-GCAGAAATCGCAAAGCTACTG-3’), C/EBPβ
(Taqman assay # Hs00270923_s1), OPN TSS (Taqman assay # AJRR84Z), OPN190
(F:CTTTATGTTTTTGGCGTCTTCCA, R: CTAGCAAAATAGGCTGTCCC), IL-6
promoter (F: 5’-GCCATGCTAAAGGACGTCACA-3’, R: 5’-
GGGCTGATTGGAAACCTTATTAAGA-3’), IL-8 promoter (F: 5’-
AAGTGTGATGACTCAGGTTTGC-3’, R: 5’-GCACCCTCATCTTTTCATTATG- 3’),
MMP1 (IDT PrimeTime® Std qPCR assay #Hs.PT.58.38692586, Probe: 5’-56-
FAM/TCCGTGTAG/ZEN/CACATTCTGTCCCTG/3IABkFQ/-3’, F: 5’-
GCCAAAGGAGCTGTAGATGTC -3’, R: 5’-GACAGAGATGAAGTCCGGTTT -3’),
CXCL5 (IDT PrimeTime® std qPCR assay #Hs.PT.58.41058007.g, Probe: 5’-
/56/FAM/CGGGGAGGG/ZEN/CAGGGAAGATG/3IABkFQ/-3’, F: 5’-
36
GAACAGGCTTTACATTCAGACAG-3’, R: 5’-GGGTTAGAGGATTGCAGAAGA-3’), IL1β
(IDT PrimeTime® std qPCR assay #Hs.PT.58.1518186, Probe: 5’-/56-
FAM/AGAAGTACC/ZEN/TGAGCTCGCCAGTGA/3IABkFQ/-3’, F: 5’-
GAACAAGTCATCCTCATTGCC-3’, R: 5’-CAGCCAATCTTCATTGCTCAAG-3’).
Microarray
Microarray analysis was performed by the Genome Technology Access Center at
Washington University.  Cells expressing shLUC were senesced using bleomycin or
Ras expression.  Further analysis was restricted to genes that were either significantly
up- or down-regulated in both bleomycin and Ras groups.  Fold changes in bleomycin
relative to untreated groups were then compared between the shLUC, shCEBP_2, and
shMYB_1 groups.  Two biological replicates for each group were analyzed.  Statistical
analysis was done using linear model fitting and the R package limma using an adjusted
p-value<0.05 as the cutoff for significance (42, 43).  GO Term Enrichment Analysis was
performed using the Gene Ontology Consortium PANTHER software version 11.1
(released 2016-10-24) and the PANTHER Overrepresentation Test (released 2016-07-
15).  The PANTHER protein class annotation was used and our datasets were
compared to the Homo Sapiens reference list with Bonferroni correction for multiple
comparisons (44).
Coculture
Coculture experiments were performed as previously described with the following
modifications (7).  A total of 1.3 × 104 fibroblasts were plated in black-walled 96-well
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plates (Fisher Scientific).  Cells were incubated in starve medium (DMEM + 1%
penicillin/streptomycin) for 3 days before the addition of HaCAT-CBR cells.  HaCAT-
CBR cells were cultured in starve medium for 24 hours before plating on fibroblasts.  A
total of 1.0 × 103 HaCAT-CBR cells were plated on fibroblasts and incubated for six
days. On day six, live-cell bioluminescence imaging was performed on an IVIS 50
(PerkinElmer; Living Image 4.3, 1 min exposure, bin8, FOV12cm, f/stop1, open
filter). D-luciferin (150mg/ml; Gold Biotechnology, St. Louis, MO) was added to black-
walled plates 10 min prior to imaging.
Statistical analysis
Data is presented as the mean ± SEM. Student’s t-test was used to determine
significance when comparing two groups.  When comparing three or more groups, one-
way ANOVA with Dunnett’s post-test was used, except where noted.  In all cases, a p-
value less than 0.05 was considered significant.
RESULTS
The OPN promoter contains a senescence response element
Given the pro-tumorigenic nature of OPN and its unique regulation among studied
SASP factors, we sought to determine the mechanism of OPN regulation during
senescence.  To do so, we used promoter reporter constructs composed of regions of
the OPN promoter driving transcription of luciferase to identify sequences in the OPN
promoter required for transcriptional activation during senescence (38).  To carry out
these analyses, BJ fibroblasts were transfected with the reporter constructs and induced
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to senesce by treatment with bleomycin for 24 hours.  Four days after the start of
bleomycin treatment, when cells displayed a senescent phenotype as demonstrated by
a flattened morphology and staining positive for senescence-associated β-galactosidase
(SA-βgal; Fig. 2.1A), we assessed luciferase activity. We used regions of the OPN
promoter spanning from the +86 nucleotide to the upstream site indicated (Fig. 2.1B).
While the +86 to -135 nucleotide region of the promoter had only ~two-fold increase in
luciferase activity in bleomycin treated cells relative to non-senescent cells, the region
spanning from +86 to -190 nucleotide had 4.9-fold increased expression in senescent
compared to non-senescent fibroblasts. The increased induction of expression
observed in response to senescence when the -135 to -190 nucleotide region was
present suggested that this region, which we termed the senescence response element
(OPN-SRE), contains important senescence-associated transcription factor binding
motifs (Fig. 2.1C).
Transfac® analysis of the OPN-SRE promoter region revealed numerous putative
binding sites for a variety of transcription factors, including HNF1, ZBTB16, HMGA1,
SOX, FOXH1, C/EBPβ, and c-Myb.  Preliminary data suggested that many of these
factors were not required for OPN induction in response to senescence (data not
shown).  Therefore, we focused on the transcription factors C/EBPβ and c-Myb.
C/EBPβ regulates the induction of numerous SASP factors including IL-6 and IL-8 in
response to oncogene induced senescence (31).  In contrast, while c-Myb
transcriptionally activates OPN in several epithelial cell models (24, 34), its roles in
fibroblasts and in senescence are poorly studied. However, c-Myb and C/EBPβ can
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interact and have been shown to co-activate transcription of several genes in other
settings (45–47). Given these data, we examined C/EBPβ and c-Myb as possible
regulators of OPN in response to senescence.
C/EBPβ is required for robust OPN expression in response to senescence
C/EBPβ regulates the induction of several SASP factors including IL-6 and IL-8 in
response to oncogene induced senescence (31, 48) and has been implicated in control
of OPN expression in other systems (32, 49, 50).  To test whether C/EBPβ was required
for the induction of OPN in response to senescence, we depleted BJ fibroblasts of
C/EBPβ using two independent shRNAs (Fig. 2.2A).  Upon the induction of
senescence, C/EBPβ-depleted cells displayed reduced OPN expression relative to
fibroblasts expressing a control short hairpin.  Indeed, shC/EBPβ cells had 42% and
77% reduced OPN induction (shCEBP_1 and shCEBP_2, respectively) compared to
shLUC expressing cells (Fig. 2.2B).  In agreement with previous studies (31), we found
that C/EBPβ depletion also reduced IL-6 (39% and 78%, shCEBP_1 and shCEBP_2,
respectively) and IL-8 (78% and 97%, shCEBP_1 and shCEBP_2, respectively)
induction in response to senescence.  Interestingly, depletion of C/EBPβ did not affect
senescence induction in our system as measured by SA-βgal and cell growth
measurement (Fig. 2.2C-D).
To confirm C/EBPβ’s role in regulating OPN, we inhibited C/EBPβ in BJ fibroblasts by
stably expressing a dominant negative form of C/EBPβ, LIP.  C/EBPβ has three
isoforms: LAP1, LAP2, and LIP (51).  LAP1 and LAP2 are transcriptional activators
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while LIP, which contains the DNA binding domain but lacks the transactivation domain,
is an inhibitory isoform that acts as a dominant negative to the activating isoforms.
Compared to empty vector controls (Vector), OPN induction was reduced by 59% and
IL-6 induction by 75% in LIP-expressing cells (DN-CEBP) in response to senescence
(Fig. 2.2E).  Importantly, inhibition of C/EBPβ did not affect senescence induction as
measured by SA-β-gal (Fig. 2F).  Thus, C/EBPβ is required for OPN, IL-6, and IL-8
induction in response to senescence, but depletion or inhibition does not prevent the
induction of senescence in our system.  C/EBPβ, therefore, represents a common factor
of the previously distinct regulatory pathways of OPN and SASP factors such as IL-6
and IL-8.
C/EBPβ binds to the OPN promoter
The promoters of OPN, IL-6 and IL-8 all contain C/EBPβ binding sites.  To test whether
C/EBPβ directly binds the OPN promoter, we used chromatin immunoprecipitation
(ChIP) in non-senescent and bleomycin-treated 293T cells. In response to bleomycin,
there was robust induction of senescence as measured by SA-βgal staining (Fig. 2.3A).
Because the upregulation of many SASP factors is transcription-dependent early after a
senescence-inducing treatment but less dependent on transcription once senescence is
fully established, we collected cells 48 h after the start of bleomycin treatment when
transcription was robust (6). Immunoprecipitation with an anti-C/EBPβ antibody that
recognizes all three C/EBPβ isoforms revealed binding of C/EBPβ to the IL-6 and IL-8
promoters as has been previously shown (Fig. 2.3B; ref. 28).  In addition, there was
significant binding to the OPN promoter in both non-senescent (0.05% input) and
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senescent (0.07% input) cells. Interestingly, binding of exogenous Flag-tagged LAP2,
the full length activating isoform of C/EBPβ, to the OPN, IL-6, and IL-8 promoters
increased in response to senescence (Fig. 2.3C). We observed this effect despite
measuring greater Flag-LAP2 expression in non-senescent cells than in senescent cells
(Fig. 2.3E).
c-Myb is required for robust OPN expression in senescent cells
Having established C/EBPβ as a regulator of OPN, we asked whether there were
additional regulators in response to senescence.  Thus, we returned to our promoter
analysis to identify additional regulators of OPN.  In addition to the C/EBPβ binding site,
the SRE of the OPN promoter contains a putative c-Myb binding sequence.  C-Myb is a
proto-oncogene transcription factor but has never been implicated in mammalian
senescence.  Furthermore, while c-Myb is not well studied in fibroblasts, it has been
shown to regulate fibrosis and many factors upregulated in fibrosis are also upregulated
in senescence (52, 53), raising the possibility that it may play a role in regulating SASP
factor expression. Importantly, c-Myb and C/EBPβ can interact and co-activate
transcription in other contexts, suggesting they may act in a similar manner in response
to senescence (45–47).
To establish a role for c-Myb in the regulation of OPN during senescence, human
fibroblasts were depleted of c-Myb using two independent short hairpins.  Using
bleomycin to induce senescence (Fig. 2.4A), we measured OPN mRNA expression by
qRT-PCR. Using two hairpins to deplete c-Myb, we observed a 37% and 45%
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(shMYB_1 and shMYB_2, respectively) reduction in c-Myb protein levels relative to γ-
actin (Fig. 2.4B), which resulted in a 64% and 77% decrease in OPN mRNA induction
relative to shLUC control (Fig. 2.4C). Importantly, depletion of c-Myb did not inhibit
senescence-induction, as measured by SA-βgal and cell growth assays, indicating that
c-Myb is necessary for OPN induction but not senescence induction (Fig. 2.4A,D),
C-Myb has not previously been reported to regulate the SASP.  Therefore, we asked
whether c-Myb regulates other SASP factors in addition to OPN.  Knockdown of c-Myb
resulted in significantly reduced IL-6 (90% and 78%, shMYB_1 and shMYB_2,
respectively) and IL-8 (89% and 84%, shMYB_1 and shMYB_2, respectively) mRNA
expression in response to senescence (Fig. 2.4C), indicating that c-Myb regulates
multiple SASP factors and suggesting that it may broadly regulate C/EBPβ-dependent
SASP factors.
c-Myb regulates OPN via direct binding and activation of the OPN promoter
To test whether c-Myb directly regulates OPN transcription, we used chromatin
immunoprecipitation (ChIP) in 293T cells ectopically expressing c-Myb. ChIP analysis
of c-Myb revealed that it is significantly bound to the OPN promoter relative to IgG
control in both non-senescent (0.007 percent input Myb relative to 0.003 IgG) and
senescent (0.014 percent input relative to 0.002 IgG; Fig. 2.5A) cells.  Additionally, c-
Myb also bound the IL-6 and IL-8 promoters at similar levels, indicating that c-Myb
directly regulates SASP factors other than OPN. Further, in senescent cells c-Myb
significantly bound the WT OPN190-luciferase promoter reporter construct compared to
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IgG controls (0.34 c-Myb percent input relative to 0.18 IgG; Fig. 2.5B).  However,
mutation of the putative c-Myb binding site on the OPN190 reporter (OPN190-MUT
MBS) eliminated c-Myb binding (0.10 Myb percent input relative to 0.08 IgG), indicating
that c-Myb binds specifically to this site.  While WT OPN190 promoter activity is
activated 4.3-fold following bleomycin treatment, OPN190-MUT MBS is not activated
(1.3-fold; Fig. 2.5C), indicating that c-Myb binding to the OPN promoter is required for
the transcriptional induction of OPN following senescence induction.
c-Myb and C/EBPβ regulate overlapping subsets of the SASP
While it has been snown that C/EBPβ regulates the SASP, c-Myb has not previously
been implicated as a SASP regulator.  To determine whether c-Myb regulates additional
SASP factors beyond OPN, IL-6, and IL-8, we performed a microarray comparing
transcript levels in non-senescent and senescent BJ fibroblasts expressing either a
control short hairpin (shLUC) or a hairpin targeting either c-Myb or C/EBPβ (shMyb_1 or
shCEBP_2, respectively).  We restricted our analysis to 834 SASP genes, those which
were significantly upregulated both by bleomycin-induced senescence and Ras-induced
senescence (Supplemental Table 2.1).  We compared the gene fold-upregulation in
bleomycin-treated cells relative to untreated cells in the shLUC, shMYB_1, and
shCEBP_2 groups.  Comparing the fold-upregulation between groups, we found that
127/834 genes were C/EBPβ-dependent (Fig. 2.6A, Supplemental Table 2.2).
Importantly, 59/834 genes were c-Myb-dependent (Supplemental Table 2.3).
Interestingly, 47/59 c-Myb-dependent genes were also C/EBPβ-dependent, suggesting
c-Myb largely regulates C/EBPβ-dependent genes.  We performed GO Term
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enrichment analysis on the SASP, C/EBPβ-dependent, and c-Myb-dependent gene
sets. There were no significant enrichments among these gene sets relative to each
other.  However, the SASP was enriched for expected terms such as chemokine,
cytokine, and extracellular matrix glycoprotein relative to the genome.  Further, both
C/EBPβ and c-Myb were similarly enriched for the terms chemokine, cytokine, and
serine protease inhibitor.
In accordance with our qPCR findings, IL-6 and IL-8 are among the C/EBPβ- and c-
Myb-dependent genes (Fig. 2.6B). However, while OPN induction was reduced in
shC/EBPβ and shMyb cells, this reduction was not significant.  This difference was
significant when measured by qPCR (Fig. 2.4C), suggesting that the microarray data
lacks sufficient power to find significance for genes with smaller changes.  Therefore,
our analysis likely underestimates the number of genes regulated by both C/EBPβ and
c-Myb.
In addition to the genes we had already studied, we used qPCR to validate CXCL5,
IL1β, and MMP1, three genes which were significantly dependent on both C/EBPβ and
c-Myb in our microarray data.  All three genes recapitulated the microarray results (Fig.
2.6C).  These data suggest that c-Myb is an important regulator of many C/EBPβ-
dependent SASP genes in addition to OPN, IL-6, and IL-8.
c-Myb and C/EBPβ knockdown inhibits preneoplastic cell growth promotion by
senescent fibroblasts
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Senescent fibroblasts promote the growth of neoplastic and preneoplastic epithelial
cells in coculture and xenograft models via secretion of SASP factors (7, 29).  Depletion
of OPN in senescent BJ skin fibroblasts is sufficient to eliminate the growth promotion
that senescent BJ fibroblasts provide to HaCAT preneoplastic keratinocytes.  Because
c-Myb and C/EBPβ regulate OPN and other SASP factors, we tested whether depletion
of c-Myb and C/EBPβ would reduce the growth advantage provided by senescent cells
using this same skin carcinoma coculture model.
HaCAT cells stably expressing click beetle red luciferase were plated on top of a
confluent monolayer of either non-senescent or senescent fibroblasts in serum-free
media and allowed to grow for six days.  Recapitulating previous work, senescent
fibroblasts dramatically increased HaCAT cell growth as measured by live cell imaging
(7, 29). However, this growth was significantly lower for HaCAT cells cocultured with
either shC/EBPβ or shMyb expressing fibroblasts (Fig. 2.7A), indicating the importance
of C/EBPβ and c-Myb in regulating the SASP and its downstream pro-tumorigenic
effects.
DISCUSSION
The SASP plays important roles in wound healing and pathology, including the
promotion of tumor development. Thus, understanding the complex regulation of the
SASP will provide opportunities for therapeutic intervention.  Many regulators of the
SASP have been identified.  However, it is clear that not all SASP factors are regulated
by the same pathways. The SASP factor OPN is a potent pro-tumorigenic factor and is
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involved in numerous other physiological and pathological pathways such as bone
turnover and the development of kidney stones (23, 54).  Previous work by our
laboratory found that OPN is not dependent on the canonical SASP regulators ATM and
NF-κB (30), illustrating that SASP factors are not subject to a single regulatory program.
We have identified C/EBPβ and c-Myb as critical regulators of the pro-tumorigenic
SASP factor OPN. Depletion of C/EBPβ using shRNA and dominant negative inhibition
significantly decreased OPN induction in response to senescence (Fig. 2.2B,E).  As has
been previously reported, C/EBPβ is also required for the induction of IL-6 and IL-8 (31).
However, in contrast to that study which used an oncogene-induced senescence model,
we did not observe a decrease in senescence induction in response to C/EBPβ
depletion or inhibition (Fig. 2.2A,D,F).  While the cause of this difference is not clear, it
may be due to differences in cell type, senescence-induction, or the level of C/EBPβ
depletion.  Nonetheless, the robust senescence induction observed, together with our
ChIP data (Fig. 2.3B-C), indicate that OPN is directly regulated by C/EBPβ and is not
simply induced indirectly by the senescence program.
While C/EBPβ has previously been reported as an important SASP regulator, very little
has been published about the mechanism of C/EBPβ activation of SASP genes.  We
observed that although there is no significant change in total C/EBPβ binding to the
OPN, IL-6, or IL-8 promoters, binding of an exogenously expressed, activating form of
C/EBPβ, Flag-LAP2, significantly increases in response to senescence (Fig. 2.3C, Fig.
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2.7B).  These data suggest that C/EBPβ regulation of SASP factor transcription may be
more complex than simple binding, but require changes in specific isoform binding.
Our data establish that c-Myb is a novel regulator of components of the SASP.
Depletion of c-Myb using shRNA significantly decreased the induction of OPN, IL-6, and
IL-8 in response to senescence (Fig. 2.4C).  An additional 57 putative target factors
were identified via microarray (Fig. 2.6A), and three of these putative targets (MMP1,
CXCL5, and IL1B) were validated with qRT-PCR (Fig. 2.6C).  The regulation of at least
some of these genes is direct, as c-Myb binds directly to the OPN, IL-6, and IL-8
promoters in both non-senescent and senescent cells (Fig. 2.5A). Interestingly, there is
an increase in promoter occupancy in senescent cells relative to non-senescent, which,
while non-significant, raises the possibility that c-Myb may increase binding to the
promoters of some SASP factors in response to senescence.  Mutation of the c-Myb
binding site on the OPN promoter disrupts this binding and abrogates promoter
activation in response to bleomycin (Fig. 2.5B-C). Together these data indicate that c-
Myb is critical for the induction of not only OPN, but a larger subset of the SASP.
Although c-Myb has not been extensively studied in fibroblasts, one of its known roles is
regulating fibrosis (52, 53).  Here we show that c-Myb regulates SASP factors, including
matrix proteins OPN and MMP1, suggesting that c-Myb plays an important role in
regulating the extracellular matrix in multiple physiological contexts.
C/EBPβ and c-Myb commonly act as co-activators of transcription (35–37).  Our data
indicate that both transcription factors are required for the induction of OPN.  In addition,
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via microarray analysis, we identified 47 additional SASP genes which are dependent
on both C/EBPβ and c-Myb (Fig. 2.6A).  Only 12 c-Myb-dependent factors were not
also C/EBPβ-dependent, indicating that c-Myb generally regulates C/EBPβ-dependent
factors.  We hypothesize that C/EBPβ and c-Myb interact to activate a cohort of SASP
factors, but more work is needed to investigate whether these mechanisms studied in
other contexts are also at play in senescent cells.
While OPN upregulation in senescence is independent of ATM and NF-κB, it does
require C/EBPβ and c-Myb for expression.  C/EBPβ and c-Myb also regulate IL-6, IL-8,
and other NF-κB-dependent genes, suggesting that there are not simply distinct SASP
master regulatory pathways, but multiple SASP regulators which act together and
separately in a complex network to regulate the individual factors that are collectively
the SASP.  More work is needed to understand the interplay among the various
regulatory pathways and which factors they regulate.
ACKNOWLEDGMENTS
We thank Paul C. Kuo for the OPN-LUC promoter constructs, Joan Massague for the
pCMV-FLAG-LAP2 and pBabe-puro-LIP plasmids, Judy Lieberman for pSIREN-RetroQ-
MYB-shRNA, and Robert Rosenberg for the pcDNA3.1-Myb plasmid. Other shRNA
constructs were obtained from the Children’s Discovery Institute’s viral vector-based
RNAi core at Washington University in St. Louis. We thank the Genome Technology
Access Center in the Department of Genetics at Washington University School of
Medicine for help with genomic analysis. The Center is partially supported by NCI
49
Cancer Center Support Grant #P30 CA91842 to the Siteman Cancer Center and by
ICTS/CTSA Grant# UL1TR000448 from the National Center for Research Resources
(NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for
Medical Research. This publication is solely the responsibility of the authors and does
not necessarily represent the official view of NCRR or NIH. We thank Lynne Marsala
for live cell imaging (supported by NIH P50 CA094056), Hayley Moore, Daniel Teasley,
Bhavna Murali, Hui Huang, Talon Trecek, and members of the ICCE Institute at
Washington University School of Medicine for experimental support and discussion.
Financial Support: NIH 5 R01 CA130919 (SAS), NIH Cellular Biochemical and
Molecular Sciences Pre-doctoral Training Grant T32 GM007067 (KCF, EA and LLA),
NIH F31 CA189669 (KCF), American Cancer Society Research Scholar Award (SAS).
The work was supported in part by the Siteman Investment Program (supported by The
Foundation for Barnes-Jewish Hospital Cancer Frontier Fund (FBJH CFF 3773);
Barnard Trust; Fashion Footwear Charitable Foundation of New York, Inc.; and, the
National Cancer Institute Cancer Center Support Grant P30CA091842, Eberlein, PI)
(SAS). Luminescent imaging was supported by NIH P50 CA094056.
50
Figure 2.1: The senescence-responsive region of the OPN promoter contains c-
Myb and C/EBPβ binding sites
A) Treatment of BJ fibroblasts with bleomycin induces a significant increase in
senescence as indicated by increased senescence-associated β-galactosidase staining,
n=3, *p<0.05. Scale bar=100 μm B) Schematic of expression of luciferase reporter
constructs that were driven by fragments of the OPN promoter spanning from nucleotide
+86 to the indicated number of bases upstream from the transcription start site (TSS;
top). BJ fibroblasts expressing the indicated promoter reporter constructs were treated
with vehicle or bleomycin to induce senescence. Relative luciferase activity in
senescent relative to non-senescent fibroblasts indicates a senescence-responsive
element (SRE) between -135 and -190 bases upstream of the TSS (bottom), n=3. C)
Schematic of OPN promoter.  The SRE includes putative binding sites for the
transcription factors c-Myb and C/EBPβ.
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Figure 2.2: C/EBPβ is required for OPN induction in response to senescence
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A) C/EBPβ protein was measured in control or shCEBP-expressing cells via Western
blot.  shCEBP_1 had 64% reduced levels of activating C/EBPβ isoforms (LAP1&2) while
shCEBP_2 had 59% reduced activating C/EBPβ isoforms, n=3. B) OPN, IL-6, and IL-8
mRNA expression were decreased in senescent shCEBP_1 and shCEBP_2 BJs
relative to control (shLUC), n=3, *p<0.05. C) Senescence-associated β-galactosidase
(SA-βgal) staining was used to measure senescence induction in BJ fibroblasts
expressing one of two independent shRNAs targeting C/EBPβ (shCEBP_1, shCEBP_2)
or a control hairpin (shLUC) and treated with bleomycin (Bleo, left).  There is no
significant difference in percent SA-βgal+ cells among any of the hairpins (right), n=3,
n.s.=non-significant, *p<0.05. Scale bar=100 μm D) Cell proliferation over four days in
non-senescent or bleomycin-treated fibroblasts was not affected by depletion of
C/EBPβ, n=3, *p<0.05. E) Expression of OPN and IL-6 are significantly reduced in
senescent cells expressing dominant negative C/EBPβ (DN-CEBP) relative to empty
vector control, n=4, *p<0.05 F) SA-βgal staining indicates no change in senescence
induction following bleomycin treatment in vector compared to DN-CEBP fibroblasts,
n=3, n.s.=non-significant, *p<0.05, ***p<0.001. Scale bar=100 μm.
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Figure 2.3: C/EBPβ isoform binds SASP promoters in senescent cells
A) Treatment of 293T HEK cells with bleomycin induces a significant increase in
senescence as indicated by increased senescence-associated β-galactosidase staining,
n=3, *p<0.05. Scale bar=100 μm. B) Chromatin immunoprecipitation (ChIP) using a
C/EBPβ antibody which recognizes all three C/EBPβ isoforms or a non-specific control
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(IgG) indicates that C/EBPβ binds to the OPN, IL-6, and IL-8 promoters in both vehicle
and bleomycin-treated 293Ts, representative experiment, n=3, *p<0.05. C) ChIP in
293Ts transfected with a Flag-tagged full length C/EBPβ isoform (Flag-LAP2).  An
antibody recognizing all three C/EBPβ isoforms (CEBP) or an anti-Flag antibody was
used to detect binding of the total C/EBPβ relative to exogenous Flag-LAP2 to the OPN,
IL-6 and IL-8 promoters in vehicle (Non-Sen) and bleomycin-treated (Sen) 293Ts.
While there was little change in total C/EBPβ bound to the OPN, IL-6, or IL-8 promoters,
Flag-LAP2 binding to all three promoters was significantly increased in senescent cells,
representative experiment, n=3, *p<0.05. D) Western blotting using an anti-Flag
antibody indicated that Flag-LAP2 expression is significantly higher in non-senescent
293Ts than senescent 293Ts, n=3.
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Figure 2.4: c-Myb regulates OPN, IL-6, and IL-8 in response to senescence
A) Senescence-associated β-galactosidase (SA-βgal) staining was used to measure
senescence induction in bleomycin-treated BJ fibroblasts expressing one of two
independent shRNAs targeting c-Myb (shMYB_1, shMYB_2) or a control hairpin
(shLUC; left).  There is no significant difference in percent SA-βgal+ cells among any of
the hairpins (right), n=3, n.s.=non-significant, *p<0.05. Scale bar=100 μm B) c-Myb
protein was measured in control or shMYB-expressing cells via Western blot.  shMYB_1
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had 37% reduced levels of c-MYB while shMYB_2 had 45% reduced c-Myb, n=3. C)
OPN, IL-6, and IL-8 mRNA expression were decreased in senescent shMYB_1 and
shMYB_2 BJs relative to control (shLUC), n=3, *p<0.05. D) Cell proliferation over four
days in non-senescent or bleomycin-treated fibroblasts was not affected by depletion of
c-Myb, n=3 *p<0.05, ***p<0.001.
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Figure 2.5: OPN induction in senescent cells requires c-Myb binding to the OPN
promoter
A) Chromatin immunoprecipitation was used to measure c-Myb binding to the OPN, IL-
6, and IL-8 promoters in 293T cells expressing exogenous c-Myb cDNA.  C-Myb
significantly binds to all three endogenous promoters, representative experiment, n=3,
n.s.=non-significant, *p<0.05. B) c-Myb binds the OPN190 promoter reporter construct
relative to IgG control.  Mutation of the c-Myb binding site eliminates binding to the
OPN190 construct, n=3, n.s.=non-significant, *p<0.05. C) Luciferase activity is
increased in senescent BJ fibroblasts expressing the WT OPN190 construct relative to
non-senescent cells, but not in fibroblasts expressing the mutant c-Myb binding site
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OPN190 construct (OPN190MUT MBS), n=4, n.s.=non-significant, *p<0.05.
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Figure 2.6: c-Myb and C/EBPβ regulate a subset of the SASP
A) A microarray was performed to compare gene expression and induction in response
to senescence among control, shCEBP_2 and shMYB_1 expressing fibroblasts.  834
genes were identified as SASP factors.  Of these, 127 were solely C/EBPβ dependent,
12 were solely c-Myb dependent, and 47 were dependent on both transcription factors.
GO Term enrichment analysis was performed. Genes were considered dependent if
their induction in response to senescence was significantly reduced in the experimental
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hairpin condition relative to control, p<0.05. B) The log2 fold change in induction
(bleomycin over non-senescent) of shLUC relative to shCEBP_2 or shMYB_1 is plotted
relative to the negative log10 of the p-value.  Genes with significantly higher (bright
colors, right) or lower (pale colors, left) induction in shLUC relative to shCEBP (circles)
or shMYB (open boxes) are indicated. C) The C/EBPβ- and c-Myb-dependent SASP
factors MMP1, CXLC5, and IL1B were validated using qRT-PCR.  Depletion of C/EBPβ
or c-Myb with two different hairpins each significantly reduced induction of these SASP
factors.
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Figure 2.7: Depletion of c-Myb or C/EBPβ inhibits preneoplastic cell growth
promotion by senescent fibroblasts
A) HaCAT keratinocytes expressing CBR luciferase were cocultured with non-
senescent or senescent BJs expressing either a control shRNA (shLUC) or shRNAs
targeting C/EBPβ (shCEBP_1 and shCEBP_2) or c-Myb (shMYB_1 and shMYB_2).
HaCAT proliferation was measured using bioluminescent imaging after six days of
coculture, shown as fold growth when cocultured with senescent fibroblasts relative to
non-senescent fibroblasts.  Depletion of either C/EBPβ or c-Myb in senescent BJs
significantly reduces the ability to promote HaCAT cell growth, n=3, *p<0.05. B)
Schematic showing the proposed model of regulation of OPN and other SASP factors
by c-Myb and C/EBPβ.  In response to senescence, the activating isoform of C/EBPβ,
LAP2, increases occupancy on the SASP promoter, inducing transcription.
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CXCL5 59.6 28.5
CXCL8 26.8 27.6
SERPINB4 98.9 25.0
IL1B 22.1 14.2
CLDN1 14.2 13.2
IL24 6.5 11.0
IL13RA2 38.9 7.9
CXCL1 3.1 7.6
EREG 16.0 6.9
IL1A 29.4 6.6
GDF15 3.9 6.5
SERPINB2 9.3 6.2
C3 2.0 6.1
LOC105369848 20.4 6.1
MMP3 9.5 5.8
ESM1 9.0 5.7
CTSS 7.5 5.4
LOC541472 2.6 5.4
SLC16A6 40.9 5.2
RRAD 4.9 4.8
ITGA2 12.5 4.7
TFPI2 6.1 4.7
C15orf48 5.1 4.5
ACPP 29.8 4.4
KCTD4 14.9 4.4
MIR222 1.9 4.3
CSF3 8.2 4.2
IL6 1.9 4.1
SPP1 4.9 4.0
HIST1H2BG 5.5 3.9
C1QTNF1 1.4 3.9
AMPD3 6.6 3.9
TMEM158 6.6 3.8
LIF 4.4 3.8
TM4SF1 11.5 3.8
LINC01021 1.5 3.7
SLC22A4 2.7 3.7
KRTAP2-3 2.0 3.7
ULBP1 4.0 3.7
KRTAP3-1 2.9 3.6
ACER2 1.5 3.5
LINC01291 2.2 3.4
PRLR 2.1 3.3
ENC1 4.3 3.3
SAT1 5.1 3.3
PAPPA 1.5 3.3
TREM1 1.4 3.3
CXCL3 2.7 3.3
CCL20 1.9 3.3
CD24 1.5 3.3
STC1 5.8 3.2
CDCP1 12.4 3.2
LRRC15 7.5 3.2
PSTPIP2 1.9 3.2
P3H2 2.9 3.2
CSF2 21.5 3.2
NFKBIZ 3.7 3.1
CYFIP2 2.2 3.1
PI3 3.1 3.1
LOC105374003 43.9 3.0
C10orf55 17.5 3.0
THSD1 1.6 3.0
CES2 1.4 3.0
IFI30 1.7 3.0
PAG1 3.6 3.0
LCE1F 416.1 2.9
TNFAIP3 2.9 2.9
DUSP4 9.2 2.9
WDR63 2.0 2.9
STEAP1 5.2 2.9
MMP1 4.3 2.9
PTGS2 2.0 2.9
PTPN22 2.7 2.9
SEC11C 3.4 2.9
LRRN3 1.7 2.8
CHST7 2.6 2.8
LPXN 4.7 2.8
PLAU 15.0 2.8
DLGAP1-AS2 2.3 2.8
ERN1 3.3 2.8
COL10A1 36.4 2.7
IRAK3 1.6 2.7
DTNA 2.3 2.7
POU2F2 5.7 2.7
MAMDC2 1.5 2.7
HIST1H2BC 3.2 2.7
LOC105374171 4.7 2.7
RRM2B 2.2 2.7
IRAK2 4.6 2.7
EHF 7.8 2.7
VTRNA1-3 1.9 2.6
HIST1H4H 2.7 2.6
TSPAN13 7.2 2.6
TNFRSF10A 2.0 2.6
STAT4 1.9 2.6
APLP1 1.3 2.5
NEFM 4.0 2.5
HIST1H2BN 2.0 2.5
CDKN1A 1.4 2.5
AOX1 1.4 2.5
GADD45A 1.7 2.5
SOD2 1.7 2.5
PHLDA1 4.7 2.5
LOC105369808 2.3 2.5
AKR1B1 2.0 2.5
LOC105369893 29.2 2.4
HSD11B1 1.6 2.4
DUSP6 9.1 2.4
TMEM132A 2.4 2.4
PMAIP1 7.0 2.4
ANOS1 19.2 2.4
RAB27B 2.3 2.4
CYP3A7 2.4 2.4
LOC105376374 9.6 2.4
RNF152 4.7 2.3
SERPINB3 5.6 2.3
TIGAR 2.0 2.3
42797 2.6 2.3
SEMA3A 5.7 2.3
MLLT11 6.3 2.3
TMEM68 1.5 2.3
INA 3.0 2.3
FJX1 3.0 2.3
SHC4 2.0 2.3
EVI2A 1.4 2.2
IL11 6.0 2.2
PARM1 1.6 2.2
STEAP2 4.0 2.2
LCE2A 39.8 2.2
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EPG5 1.9 2.2
ZC3H12C 4.1 2.2
DYRK3 2.2 2.2
ADRB2 1.8 2.2
NRG1 4.4 2.2
DHRS7 2.3 2.1
LOC105369340 2.0 2.1
POPDC3 5.9 2.1
GM2A 1.8 2.1
RHBDF2 2.5 2.1
HIST2H2BE 2.2 2.1
RNF19B 1.7 2.1
GK 2.9 2.1
MAP3K5 3.4 2.1
EPHA2 2.1 2.1
BCL2L1 2.0 2.1
ITGA6 4.6 2.1
PID1 3.1 2.1
LOC105376626 7.5 2.1
IER3 2.9 2.1
CASP3 3.6 2.1
ABL2 2.6 2.1
DGKA 1.4 2.1
PCDH9 4.2 2.1
FOLR3 1.8 2.1
GDNF 2.2 2.1
ARHGEF28 5.0 2.1
ANGPTL4 1.3 2.1
SMURF2 3.2 2.1
C8orf4 1.8 2.1
OR51A4 1.6 2.0
ZC3H12A 2.2 2.0
DLL4 4.6 2.0
RAP1GAP2 2.0 2.0
ATP6V0A1 2.7 2.0
FAM180A 1.8 2.0
LOC105374433 1.6 2.0
PLK3 2.5 2.0
SNORA14B 2.7 2.0
THEMIS2 3.0 2.0
HERC5 1.8 2.0
FBXL19-AS1 1.4 2.0
NPC1 2.0 2.0
DOCK5 1.9 2.0
NCEH1 2.0 2.0
LOC105376236 1.5 2.0
ATP13A3 2.4 2.0
SVIL 3.4 2.0
PIM2 2.0 2.0
HBEGF 1.4 2.0
ANPEP 3.8 2.0
PLD1 1.4 2.0
NT5E 3.4 2.0
ABCA1 3.2 2.0
TNFRSF10D 3.3 2.0
SUSD6 1.5 2.0
DUSP5 4.8 2.0
PGF 1.5 2.0
PLAT 2.1 2.0
OGFRL1 2.3 1.9
FBXO22-AS1 2.0 1.9
ODC1 3.5 1.9
TNFRSF10B 1.4 1.9
MIR4482 2.5 1.9
DNER 2.0 1.9
BCL2A1 4.4 1.9
NOMO1 1.5 1.9
MMP16 2.4 1.9
SNORD66 2.9 1.9
ABLIM3 3.6 1.9
LOC100507006 1.7 1.9
SLC39A14 1.7 1.9
TM7SF3 1.5 1.9
SLC9A1 2.3 1.9
ITGA3 2.5 1.9
LOC105373723 1.6 1.9
LAPTM5 2.0 1.9
SERPINB7 1.8 1.9
TAF13 3.0 1.9
SIPA1L3 3.3 1.9
ABTB2 1.4 1.9
PTCHD4 1.5 1.9
DAZL 7.1 1.9
METTL6 1.8 1.9
PRKX 1.6 1.8
MT1L 4.9 1.8
LOC105379676 1.9 1.8
CPEB4 1.9 1.8
LOC105376694 5.0 1.8
TP53I3 1.5 1.8
STYK1 2.0 1.8
C16orf52 2.2 1.8
LOC101926893 1.9 1.8
TMEM154 6.9 1.8
CCND1 2.1 1.8
PNP 3.4 1.8
MYDGF 1.4 1.8
TRIB1 3.4 1.8
FBXO22 1.5 1.8
HIPK2 1.9 1.8
EML2 1.7 1.8
CYB5R2 2.0 1.8
SQRDL 1.7 1.8
LRP8 3.0 1.8
LUCAT1 1.7 1.8
GXYLT1 1.4 1.8
IGF2R 2.5 1.8
TPCN1 1.7 1.8
LOC105379695 2.3 1.8
SGTB 1.7 1.8
ERO1B 1.6 1.8
RASSF8 2.4 1.8
SLC8A1-AS1 2.0 1.8
HSPH1 2.0 1.8
CYB5R1 1.5 1.8
FBXO32 1.9 1.8
NEFL 9.2 1.8
KYNU 4.0 1.8
ATG4A 2.2 1.8
EDA2R 1.3 1.8
RETSAT 1.4 1.8
AIM1 2.0 1.8
TMEM38B 2.8 1.7
CYLD 1.7 1.7
LOC105369568 3.9 1.7
MIR146A 9.4 1.7
RPSAP52 1.6 1.7
SLC20A1 4.6 1.7
NMNAT2 1.6 1.7
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PLAUR 2.4 1.7
MIR4451 2.2 1.7
INHBA 6.1 1.7
ARHGAP22 3.6 1.7
PLA2G4C 2.0 1.7
HAGH 1.3 1.7
TNIP1 1.7 1.7
GRAMD1B 1.9 1.7
EMC7 1.5 1.7
MMP12 13.1 1.7
ADGRE2 3.5 1.7
LOC105374745 3.8 1.7
DCBLD2 5.3 1.7
MAFF 2.0 1.7
HAS2 3.3 1.7
GSTO1 2.4 1.7
LINC01002 2.0 1.7
WDFY2 2.1 1.7
TSSC2 1.6 1.7
RND3 1.3 1.7
CPED1 2.3 1.7
MYOCD 1.6 1.7
SLC11A2 1.3 1.7
PLCB4 1.4 1.7
LAMC2 2.9 1.7
ADAM23 1.6 1.7
ABCA13 1.5 1.7
ASB5 3.3 1.7
POMGNT1 1.7 1.7
C9orf72 2.4 1.7
MYO6 1.4 1.7
SRA1 1.9 1.7
PROCR 2.1 1.7
CDIP1 1.5 1.7
DPP4 1.5 1.7
SERPINB10 1.4 1.7
CD274 6.9 1.7
AGTRAP 1.3 1.7
DCUN1D3 2.0 1.7
SESN2 1.4 1.7
MAP7 1.4 1.7
LOC101929470 1.8 1.7
NEDD4L 1.8 1.7
NFKBIA 1.4 1.7
C17orf89 1.3 1.7
PGPEP1 1.5 1.7
GPR183 3.5 1.7
PLEK2 15.7 1.7
ORMDL2 1.8 1.6
RAB3B 1.4 1.6
CITED4 4.0 1.6
DNAJB9 1.6 1.6
EVC 1.3 1.6
RRS1 1.7 1.6
GLA 2.6 1.6
LOC644135 2.2 1.6
UXS1 1.5 1.6
HK2 1.7 1.6
UCN2 3.7 1.6
CDA 1.7 1.6
WTAPP1 2.7 1.6
NOMO2 1.4 1.6
STK4 1.6 1.6
CABYR 1.4 1.6
YRDC 2.3 1.6
MTHFD2L 1.9 1.6
ETV1 4.3 1.6
MAP4K3 1.5 1.6
ATP2B1 2.5 1.6
PTP4A1 1.6 1.6
TNFRSF21 16.8 1.6
MICA 2.0 1.6
LOC101927121 1.7 1.6
DAGLB 1.4 1.6
NOMO3 1.4 1.6
PSMD2 2.3 1.6
DYNC1H1 2.0 1.6
ZNF468 1.3 1.6
KCTD1 1.3 1.6
SLC31A2 1.6 1.6
SRXN1 1.8 1.6
SLC4A7 1.4 1.6
ZCCHC6 2.1 1.6
RALA 3.4 1.6
E2F7 10.3 1.6
KIF21A 1.8 1.6
ELK3 1.6 1.6
MRPL39 1.5 1.6
UHRF1BP1L 1.6 1.6
NSF 1.6 1.6
MAP2K3 2.0 1.6
AEN 1.5 1.6
EPT1 2.1 1.6
OSGIN2 2.4 1.6
GPR4 6.7 1.6
TMEM63B 1.3 1.6
MYCT1 1.7 1.6
FEZ1 1.6 1.6
OSTM1 1.7 1.6
ETV4 3.1 1.6
PNPO 1.5 1.6
HERC4 1.4 1.6
ZNF267 1.6 1.6
HMGA2 2.5 1.6
WDR66 1.6 1.6
EAF1 1.8 1.6
SDC1 1.5 1.6
NOG 3.3 1.6
PSME4 1.8 1.6
C2orf81 2.2 1.6
NFKB2 1.6 1.6
TOP1 2.2 1.6
ITPRIP 2.6 1.6
ZPR1 2.1 1.6
LOC105377023 1.3 1.6
CHMP5 1.8 1.6
FCRLB 1.6 1.6
PPP1R15A 1.8 1.6
LOC101928820 2.1 1.6
LOC105369844 3.3 1.6
RABGGTA 1.4 1.6
PDGFC 1.4 1.6
GSAP 2.4 1.6
WDR43 1.4 1.6
MCTP1 7.7 1.5
ZNF432 1.4 1.5
ADIRF 1.7 1.5
KIF3B 1.6 1.5
FAM214B 2.1 1.5
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UCHL3 2.0 1.5
EIF5A2 1.4 1.5
SOWAHC 1.6 1.5
ITPR3 1.7 1.5
BCAP31 1.6 1.5
RPLP0P2 12.1 1.5
SRPX2 1.6 1.5
C6orf1 1.3 1.5
MCC 1.5 1.5
HYOU1 2.0 1.5
GLRX 2.0 1.5
PPP3CC 1.4 1.5
PI4K2A 1.6 1.5
MYO5A 2.5 1.5
LINC00589 1.5 1.5
CREM 1.6 1.5
MAFK 1.5 1.5
FXR2 1.7 1.5
TNFAIP2 1.3 1.5
PAK2 1.4 1.5
ELL 1.9 1.5
ANKRD31 1.5 1.5
LOC105369313 2.8 1.5
LINC01204 2.1 1.5
FOSL1 1.7 1.5
LOC101928461 1.9 1.5
STEAP3 5.0 1.5
SCARB1 2.1 1.5
PARD6B 2.2 1.5
CORO2A 1.6 1.5
SLC35G2 1.5 1.5
TCEB3 1.5 1.5
STX3 1.5 1.5
DGKE 2.1 1.5
ARID3A 1.7 1.5
TRMT6 2.3 1.5
DNAJB11 1.4 1.5
MKLN1-AS 1.3 1.5
ATP6AP1 1.2 1.5
DDA1 2.0 1.5
NDUFAB1 2.0 1.5
GSS 1.9 1.5
DNAJC3 1.3 1.5
EGFR 1.4 1.5
GFM2 1.9 1.5
42798 1.3 1.5
AK5 1.9 1.5
LOC105369204 1.5 1.5
UBA6 2.1 1.5
NCLN 1.7 1.5
CLCA4 1.4 1.5
POLR3A 2.3 1.5
HSPA13 1.5 1.5
UBASH3B 1.6 1.5
ETNK1 1.9 1.5
FUCA2 1.3 1.5
DOCK4 12.8 1.5
NAV3 3.6 1.5
SPRY2 5.1 1.5
RIPK2 2.1 1.5
CNST 1.4 1.5
LURAP1L 1.3 1.5
PPFIBP1 1.5 1.5
ITPR2 2.0 1.5
PTPN1 1.9 1.5
UBE2M 1.9 1.5
ZNF276 1.5 1.5
FAM210B 3.5 1.5
NKX3-1 1.3 1.5
EDEM3 1.9 1.5
NR1D1 1.5 1.5
PWARSN 2.2 1.5
ABHD5 1.7 1.5
MYO10 2.6 1.5
PEX19 1.2 1.5
LOC100505622 1.5 1.5
MAP1A 1.8 1.5
ABHD3 1.7 1.5
PPP2R1B 1.5 1.5
NFKBIB 1.7 1.5
ATF3 1.4 1.5
BHMT2 2.9 1.5
GPR3 2.8 1.5
SCAMP3 1.3 1.5
LOC105376382 5.9 1.5
NEK10 1.6 1.5
LOC105379272 1.6 1.5
NEU1 1.7 1.5
SQSTM1 1.5 1.5
MAPKBP1 1.4 1.5
GDF11 1.3 1.5
SLFN5 1.6 1.5
LIG4 1.6 1.5
SMOX 1.7 1.5
PITPNC1 4.2 1.5
TLDC1 1.4 1.5
C15orf54 2.6 1.5
NCR3LG1 1.4 1.5
TNFAIP1 1.2 1.5
NIPA1 1.3 1.5
PRMT5 1.5 1.5
UHMK1 1.7 1.5
SATB2 2.6 1.5
DAP3 1.6 1.5
C3orf52 2.1 1.5
FLJ42627 1.4 1.5
METTL8 1.4 1.5
PDIA4 1.7 1.5
TBC1D9 1.7 1.5
DEDD2 1.4 1.5
FHOD3 2.5 1.5
G6PC 1.3 1.5
PFN2 1.3 1.5
ZNF622 2.1 1.5
C18orf8 1.4 1.5
TAB3 1.5 1.5
MAFG 1.6 1.5
ASB1 1.6 1.5
FAM214A 1.5 1.4
PNO1 2.0 1.4
ARFGEF2 1.4 1.4
MXD1 1.5 1.4
SLC22A1 1.4 1.4
TSPYL1 1.6 1.4
MSC 2.1 1.4
TOR1AIP2 1.4 1.4
PIP4K2C 1.5 1.4
MSI2 2.3 1.4
MFSD2A 1.6 1.4
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PTPRF 1.3 1.4
COQ10B 2.1 1.4
PSMC5 1.5 1.4
CHMP1B 1.6 1.4
PSMC4 1.8 1.4
NFKBIE 1.3 1.4
MYEF2 1.4 1.4
FRMD5 1.7 1.4
MORN4 1.5 1.4
BVES 2.6 1.4
LOC101928225 1.5 1.4
PAQR5 1.5 1.4
NFE2L1 1.3 1.4
LOC105373813 1.4 1.4
WIPI1 1.5 1.4
PTRH2 1.9 1.4
TUSC2 1.5 1.4
KLHL32 1.4 1.4
CEP104 1.3 1.4
CCBE1 2.4 1.4
GGT3P 1.6 1.4
TERF2IP 1.6 1.4
SLC37A2 2.5 1.4
ASCC3 1.4 1.4
SEC23B 2.2 1.4
ELOVL4 2.0 1.4
MCL1 2.0 1.4
HIVEP2 1.3 1.4
CMTM4 1.4 1.4
MTOR 1.8 1.4
ZNF121 1.6 1.4
ACSL4 1.5 1.4
ADGRA3 1.6 1.4
RGAG4 1.6 1.4
FIBCD1 1.9 1.4
ATG2A 1.5 1.4
PDLIM4 1.9 1.4
MIR2909 1.5 1.4
TMEM131 1.8 1.4
PPIF 3.4 1.4
EMC1 1.4 1.4
ASAP2 2.0 1.4
GTF2F2 1.5 1.4
PSMD14 2.0 1.4
LOC105372190 2.0 1.4
SUCO 1.6 1.4
PKIA 6.4 1.4
SLC39A2 1.5 1.4
LAMA1 1.5 1.4
MMP14 2.0 1.4
LOC105374556 2.7 1.4
UNC13B 1.6 1.4
SENP5 1.6 1.4
LRP10 1.2 1.4
GABARAPL2 1.7 1.4
HMGXB3 2.5 1.4
URB1-AS1 1.5 1.4
TRIM25 1.5 1.4
CEP170B 1.2 1.4
SREK1IP1 1.5 1.4
SPRY4 4.3 1.4
TRIM23 1.3 1.4
PLEKHB2 2.1 1.4
EMP1 1.9 1.4
SLC35D1 1.4 1.4
SPATA17 1.6 1.4
SERINC2 2.7 1.4
UBXN8 1.5 1.4
SEC61A2 1.7 1.4
FADS1 1.7 1.4
AMN1 2.3 1.4
UST 2.1 1.4
IGDCC4 1.6 1.4
ECE1 1.6 1.4
FMN1 2.0 1.4
SMTN 1.5 1.4
NRIP3 4.9 1.4
DENND2A 2.7 1.4
DKK2 2.5 1.4
GALNT15 1.7 1.4
SNORD116-12 1.4 1.4
IL4R 1.6 1.4
LARP4 1.4 1.4
SBNO1 1.7 1.4
EDEM1 2.4 1.4
HMGA1 2.0 1.4
PSMD3 1.6 1.4
ERRFI1 4.6 1.4
DPP9 1.9 1.4
NLRP1 1.7 1.4
FMNL2 3.8 1.4
GTPBP4 1.9 1.4
TANC1 1.3 1.4
PIKFYVE 1.5 1.4
BTBD9 1.3 1.4
G0S2 3.1 1.4
SDF2L1 1.9 1.4
CCNH 1.3 1.4
DBNDD1 1.7 1.4
HS3ST3B1 2.3 1.4
SAMD8 1.8 1.4
UBALD2 2.2 1.4
HTT 2.1 1.4
ATP1B3 1.4 1.4
CLDN12 1.3 1.4
STXBP1 2.0 1.4
OXSR1 1.6 1.4
RNF181 1.4 1.4
GDPD1 2.5 1.4
EFTUD1 1.6 1.4
FGFR1OP 1.4 1.4
HSPA5 1.7 1.4
ZFAND2A 1.5 1.4
SDE2 1.9 1.4
KLHL21 1.3 1.4
QSOX2 1.8 1.4
IDS 1.5 1.4
WNK4 1.4 1.4
ZMYND8 1.8 1.4
TMEM8A 1.4 1.4
SECISBP2 1.4 1.4
MAP4K4 1.5 1.4
PPTC7 1.6 1.4
ITPKC 1.3 1.4
PISD 1.4 1.4
TFRC 1.6 1.4
SELPLG 1.3 1.4
TMCO1 1.4 1.4
WWC3 1.4 1.4
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ZDHHC5 1.3 1.4
ATP6V1E1 1.6 1.4
CRADD 2.1 1.4
TOMM34 2.4 1.4
TMEM33 2.1 1.4
MTF1 1.4 1.4
GCC2 1.2 1.4
ANKRD52 1.7 1.4
LINC00884 1.2 1.4
PLCXD1 2.5 1.4
BAZ1A 1.6 1.4
CD109 1.3 1.4
GFPT1 1.7 1.4
NEDD4 1.4 1.4
GSG1 1.4 1.4
UAP1 1.4 1.4
LYST 1.8 1.4
FKBP4 2.0 1.4
BBS7 1.5 1.4
PIEZO1 1.3 1.4
RAB3IP 1.3 1.4
FBXO28 2.2 1.4
JARID2 1.8 1.4
RICTOR 1.5 1.4
AVL9 1.8 1.4
AUP1 1.4 1.4
TMEM2 1.8 1.4
MT2A 1.5 1.4
ARSG 1.8 1.4
NXPE3 1.3 1.4
ISOC1 3.1 1.4
PRKCD 1.6 1.4
RUSC2 1.4 1.4
BTN2A2 1.9 1.4
TSPAN14 2.9 1.4
GTF2B 1.5 1.4
HDAC9 1.5 1.4
VEPH1 3.0 1.4
JADE2 1.3 1.4
METTL13 1.3 1.4
DNAJC5 1.4 1.4
SLC3A2 1.5 1.4
RCL1 1.5 1.4
SLC17A5 1.4 1.4
UFD1L 1.6 1.3
CCL5 1.4 1.3
ORAOV1 1.7 1.3
BAZ2A 1.4 1.3
SLC33A1 1.7 1.3
RPRD1A 1.7 1.3
CHMP4C 1.4 1.3
BNC1 6.7 1.3
UGGT1 1.4 1.3
MAST4 1.4 1.3
CCND2 1.4 1.3
SLC2A6 2.0 1.3
TSTA3 1.2 1.3
ERLEC1 1.3 1.3
CD44 1.7 1.3
YIPF6 1.4 1.3
STYXL1 1.5 1.3
CUBN 1.9 1.3
KDSR 1.2 1.3
SMURF1 1.5 1.3
SRP54 1.6 1.3
PWAR5 2.6 1.3
ORAI1 1.5 1.3
SPTY2D1 1.5 1.3
COX7A2 1.5 1.3
TFAP2C 2.0 1.3
CDC37 1.6 1.3
CISD1 1.6 1.3
TRIM37 1.4 1.3
FAM91A1 1.7 1.3
HIST1H2AC 1.3 1.3
TOR4A 1.4 1.3
SERP1 1.3 1.3
AFF1 1.5 1.3
DESI1 1.8 1.3
PFKFB3 2.0 1.3
PLOD2 1.5 1.3
ARHGAP18 2.0 1.3
KLHL18 1.7 1.3
AKIRIN1 1.8 1.3
EIF1AY 1.6 1.3
EPB41L4B 1.5 1.3
PSMB7 1.5 1.3
HSPA9 1.7 1.3
TMED5 1.5 1.3
FAM96B 1.7 1.3
KIAA1217 1.3 1.3
TMED9 1.3 1.3
WSB2 1.3 1.3
ACO1 1.5 1.3
PTCHD3 1.4 1.3
ZBTB21 2.0 1.3
ATP6V1D 1.6 1.3
LOC105370145 1.3 1.3
PINK1 1.5 1.3
SLC4A4 2.8 1.3
IPPK 1.5 1.3
FAM129B 1.4 1.3
XPC 1.4 1.3
H2AFJ 1.3 1.3
ATP2C1 1.3 1.3
LHFPL2 1.8 1.3
ABHD2 1.5 1.3
CLCN3 1.4 1.3
BAK1 1.6 1.3
SMCR8 1.5 1.3
MOXD1 1.6 1.3
GSK3B 1.4 1.3
MBOAT7 1.3 1.3
CPNE3 2.3 1.3
LGALSL 1.5 1.3
CSRNP1 2.4 1.3
PRDM4 1.3 1.3
FLJ32255 1.4 1.3
TXNRD1 2.3 1.3
CANT1 1.4 1.3
SPIRE1 1.7 1.3
SFXN4 1.3 1.3
MCFD2 1.2 1.3
SEC14L2 1.3 1.3
PDHX 1.4 1.3
LRRC36 1.3 1.3
UBR4 1.5 1.3
SYNRG 1.4 1.3
UROD 1.4 1.3
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SYNE1 1.2 1.3
LOC102723721 1.4 1.3
PCNXL4 1.4 1.3
ACO2 1.4 1.3
SIK3 1.3 1.3
PHYH 1.4 1.3
PIN1 1.3 1.3
GAPVD1 1.6 1.3
MYBBP1A 1.6 1.3
RPTOR 1.3 1.3
PLAA 1.4 1.3
KCNMA1 1.7 1.3
PSEN2 1.3 1.3
DUSP1 1.4 1.3
CPEB1 1.9 1.3
TMEM120B 1.4 1.3
SERPINE1 2.1 1.3
KLC1 1.4 1.3
COQ6 1.3 1.3
TMEM57 1.4 1.3
ALG2 1.4 1.3
TMBIM1 1.2 1.3
GRPEL1 2.0 1.3
MLLT4 1.4 1.3
ATP6V1H 1.9 1.3
C2CD2L 1.8 1.3
PHLDA2 3.4 1.3
PVR 2.0 1.3
SLC19A2 1.4 1.3
CES1P1 1.3 1.3
PITRM1 1.3 1.3
DYRK1B 1.3 1.3
QPCTL 2.0 1.3
UEVLD 1.3 1.3
VEGFC 2.5 1.3
B4GALT7 1.2 1.3
VCP 1.4 1.3
BECN1 1.2 1.3
FXYD5 1.4 1.3
EIF4E 1.8 1.3
LOC727896 1.7 1.3
USP36 1.4 1.3
MICALL1 1.2 1.3
RASA2 1.3 1.3
ADIPOR1 1.3 1.3
SLAIN2 1.5 1.3
SLC22A5 1.2 1.3
CCT3 1.7 1.3
P4HA2 1.3 1.3
TRAF3IP2 1.3 1.3
TRMT1 1.7 1.3
DIS3 1.5 1.3
UCK2 1.7 1.3
ALAS1 1.6 1.3
CCNDBP1 1.2 1.3
ICOSLG 1.3 1.2
PTAR1 1.7 1.2
SLC30A7 1.7 1.2
GHITM 1.5 1.2
NRDC 1.4 1.2
Supplemental Table 2.2: C/EBPβ-dependent SASP factors
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CXCL5
EREG
SERPINB2
CXCL8
IL13RA2
SERPINB4
CXCL1
MMP1
LPXN
TMEM158
IL24
TM4SF1
ESM1
LOC105376382
IL1B
STC1
TFPI2
LOC105376374
CTSS
ACPP
C3
PTGS2
CDCP1
CSF2
SLC22A4
MMP3
CYB5R2
PI3
RNF152
NFKBIZ
DENND2A
SOD2
FAM180A
CSF3
ANLN
C2orf81
LCE2A
DTNA
KIF2C
HMGA1
MAP3K5
AKR1B1
ITGA6
ODC1
LINC01291
PLAT
CPED1
SMURF2
TREM1
HAS2
PHLDA1
FJX1
CXCL3
CEP55
PLAU
ANPEP
TNFAIP3
DUSP6
FHOD3
CDK1
IRAK3
PID1
ITGA2
SEMA3A
VEPH1
LIF
IL1A
DLL4
AIM1
APCDD1
SPC24
PLK1
NT5E
FOSL1
CLDN1
AMPD3
CCL20
LOC105374171
RGCC
ERRFI1
SLC8A1-AS1
LOC105369848
CDKN3
OGFRL1
NCEH1
EMP1
COL10A1
SHCBP1
TOP2A
ELK3
SHC4
TMEM132A
PAQR5
ARHGAP18
RPSAP52
IL6
C10orf55
AOX1
IL11
PRLR
TRIM55
PLEK2
SERPINB3
ETV4
ANOS1
RASSF8
PDIA4
SLC39A14
WDFY2
HSD11B1
OR51A4
RIPK2
LCE1F
LMNB1
MARCH3
AK5
APLP1
Supplemental Table 2.2: C/EBPβ-dependent SASP factors
70
UAP1
INA
DUSP4
SLC16A6
SLC35G2
NEDD4L
CASP3
PDLIM4
ENC1
FCRLB
Supplemental Table 2.3: c-Myb-dependent SASP factors
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CXCL5
IL24
SERPINB4
ACPP
SERPINB2
CXCL1
STC1
TM4SF1
IL13RA2
C3
EHF
CXCL8
CSF3
PI3
CTSS
CXCL3
COL10A1
EREG
CSF2
IL6
DTNA
PTGS2
IL1B
TMEM158
SLC16A6
TFPI2
CDCP1
LOC541472
C1QTNF1
SLC22A4
TMEM132A
SOD2
OR51A4
LOC105376374
FHOD3
P3H2
LCE1F
AMPD3
ANPEP
STEAP2
NFKBIZ
LCE2A
CCL20
LIF
MMP1
TREM1
TNFRSF21
GALNT15
RNF152
ATP13A3
SAT1
ARHGEF28
AOX1
SHC3
CPED1
LPXN
GM2A
IL11
MAP3K5
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INTRODUCTION
The critical role the tumor microenvironment (TME) plays in disease is underscored by
findings that changes within stromal cells can predict clinical outcome (1-3).  For this
reason, many groups have focused on how various stromal cell types impact
tumorigenesis.  For example, activated fibroblasts isolated from carcinomas (cancer-
associated fibroblasts or CAFs) promote preneoplastic cell growth and increase tumor
cell migration, invasion, and angiogenesis (4). Likewise, senescent fibroblasts, which
are also found in human tissue (5), support tumorigenesis through the promotion of
growth, invasion, and angiogenesis (6-8).  Intriguingly, both senescent fibroblasts and
CAFs express a plethora of pro-tumorigenic factors and in senescent cells this is
referred to as the senescence-associated secretory phenotype (SASP) (6, 9).
There is significant overlap between the pro-tumorigenic factors expressed in CAFs and
senescent cells.  Expression array analyses of human fibroblasts treated with granulin,
which renders a CAF-like phenotype (10), and fibroblasts isolated from human tumors
reveal that both populations express SASP factors ((11, 12) and reviewed in (13)). In
addition, CAFs isolated by laser capture micro-dissection (LCM) or via cell surface
marker expression similarly display SASP factor expression (1-4, 14).  Finally, cells that
fail to enter senescence following exposure to a senescence-inducing stress robustly
express SASP factors (15, 16), indicating that entrance into senescence is not a
prerequisite for SASP expression.  Together, these observations raise the possibility
that the mechanisms that govern SASP expression are conserved in many tumor-
promoting fibroblasts and are not dependent upon the induction of senescence.  Thus,
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identifying mechanisms that activate and sustain SASP expression will have a profound
impact on our understanding of the development of a pro-tumorigenic TME and the
identification of novel therapeutic targets.
Despite the profound impact the pro-tumorigenic SASP has on tumor cell growth and
progression, the mechanisms that lead to its activation and maintenance remain poorly
understood.  The majority of regulatory pathways elucidated thus far have focused on
SASP factor transcription, specifically by NFκB and C/EBPβ (15-19). NFκB’s
transcriptional activation of the SASP is dependent on the mitogen-activated protein
kinase p38 (p38MAPK) and the DNA-damage response protein ATM (19). However, in
other systems p38MAPK facilitates expression of cytokines including IL6 by impacting
post-transcriptional mRNA stability, possibly through the RNA binding-protein AUF1 (20-
22). Post-transcriptional regulation of the SASP by p38MAPK has yet to be
investigated.
Given the importance of the SASP on stromal-supported tumorigenesis, we investigated
the impact of p38MAPK on SASP-mediated tumor promotion.  We demonstrate that
inhibition of p38MAPK activity abrogates the tumor promoting capacity of senescent
fibroblasts.  Furthermore, inhibiting p38MAPK in CAFs inhibits their tumor promoting
abilities, demonstrating for the first time that regulatory mechanisms elucidated in
senescent stroma are applicable in CAFs.  Finally, we elucidate a p38MAPK-dependent
post-transcriptional SASP regulatory pathway that modulates RNA-binding protein
activity.
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METHODS
Cell lines and treatments
BJ human foreskin fibroblasts were obtained from Dr. Robert Weinberg (Massachusetts
Institute of Technology, Cambridge, MA) and were cultured as previously described
(23).  IMR90 human lung fibroblasts were purchased from ATCC (Manassas, VA) and
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10%
FBS (Sigma, St. Louis, MO) and 1% penicillin/streptomycin.  Patient-derived breast
cancer-associated fibroblasts were purchased from Asterand (Detroit, MI) and cultured
in DMEM supplemented with 10% FBS, 1 μg/mL hydrocortisone, 5 μg/mL transferrin, 5
μg/mL insulin, and 1% penicillin/streptomycin.  Fibroblasts were treated with bleomycin
sulfate (100 μg/mL, Sigma, St. Louis, MO) for 24 hours, followed by incubation in
normal culture medium for the time points indicated.  Fibroblasts were treated with
actinomycin D (10 μg/mL, Sigma, St. Louis, MO) for 24 hours, SB203580 (10 μM,
Millipore, Billerica, MA) for 48 hours, or CDD-111 (also referred to as SP-006, 1 μM,
Confluence Life Sciences, St. Louis, MO) for 48 hours unless indicated otherwise.
SB203580 and CDD-111 were replenished daily. Fibroblasts were treated with 2 fresh
changes of 4 mM sodium butyrate (NaB, Sigma, St. Louis, MO) for 72 or 120 hours.
RNA was isolated using TRI Reagent (Life Technologies, Carlsbad, CA) at the time
points indicated. HaCaT preneoplastic keratinocyte cells (obtained from Dr. Norbert E.
Fusenig, German Cancer Research Center, Heidelberg, Germany) stably expressing
click beetle red (CBR) luciferase (HaCat-CBR) (16) were grown in DMEM supplemented
with 10% heat-inactivated FBS and 1% penicillin/streptomycin (Sigma, St. Louis, MO).
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BPH1 preneoplastic prostate epithelial cells (obtained from Dr. Robert Weinberg,
Massachusetts Institute of Technology, Cambridge, MA) stably expressing CBR
luciferase (BPH1-CBR) were growth in DMEM supplemented with 10% non-heat
inactivated FBS and 1% penicillin/streptomycin.  All cells were cultured at 37 °C in 5%
carbon dioxide and 5% oxygen. No cell lines used were authenticated.
Plasmids
The luciferase reporter construct fused to the 3’ UTR of IL6 (lucIL6) was a gift from Dr.
Nicholas Davidson (Washington University School of Medicine, St. Louis, MO) and was
subcloned into the EcoRI site of pBABE-hygro.  Luciferase reporter constructs fused to
the 3’ UTR of GMCSF or GAPDH were purchased from Switch Gear Genomics (Menlo
Park, CA) and were subcloned in to pBABE-hygro using the SnabI and SalI restriction
sites.  Short hairpin RNA sequences targeting human AUF1 (shAUF1A: 5’-
AGAGTGGTTATGGGAAGGTAT-3’, shAUF1B: 5’-AGTAAGAACGAGGAGGATGAA-3’),
p38 (5’-GCCGTATAGGATGTCAGACAA-3’) and Hsp27 (5-
CCCGGACGAGCTGACGGTCAA-3’) were obtained from the Children’s Discovery
Institute’s viral vector-based RNAi core at Washington University in St. Louis, and were
supplied in the pLKO.1-puro backbone. Luciferase reporter assays were performed
using a plasmid containing an NFκB-responsive promoter driving expression of firefly
luciferase (NFκB-luc) and a plasmid encoding Renilla luciferase driven by the thymidine
kinase promoter, obtained from Dr. David Piwnica-Worms (Washington University
School of Medicine, St. Louis, MO).
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Senescence-associated β-galactosidase (SA-β-gal) staining
SA-β-gal staining was carried out as described previously (23).
Quantitative PCR
cDNA synthesis and quantitative PCR was performed using previously published
protocols and manufacturers’ instructions (42) (SYBR Green, Life Technologies,
Carlsbad, CA).  Primers for GAPDH (F: 5’-GCATGGCCTTCGGTGTCC-3’, R: 5’-
AATGCCAGCCCCAGCGTCAAA-3’), IL6 (F: 5’-ACATCCTCGACGGCATCTCA-3’, R:
5’-TCACCAGGCAAGTCTCCTCA-3’), IL8 (F:  5’-GCTCTGTGTGAAGGTGCAGT-3’, R:
5’-TGCACCCAGTTTTCCTTGGG-3’), MMP3 (F: 5’-
GTTTTGGCCCATGCCTATGCCCC-3’, R: 5’-GGAGTCAGGGGGAGGTCCATAGAGG-
3’), CCL20 (F: 5’-CTGCGGCGAATCAGAAGCAGC-3’, R: 5’-
CCTTCATTGGCCAGCTGCCGT-3’), lucIL6 (F: 5’-CGGGCGCGGTCGGTAAAGTT-3’,
R: 5’-AAACAACAACGGCGGCGGGA-3’), and lucGMCSF and lucGAP (F: 5’-
GAGAAACATGCGGAGAACGC-3’, R: 5’-AGCATGCACGATAGCCTTGA-3’) were
purchased from IDT.  GMCSF cDNA was amplified using a Taqman probe/primer set
(catalog number Hs00929873_m1, Life Technologies, Carlsbad, CA).
ELISA
Conditioned medium was generated by incubating cells for 24 hours in serum-free
medium.  Following collection, secreted IL6 protein levels were measured using the
human IL6 Quantikine ELISA kit (catalog number D6050, R&D Systems, Minneapolis,
MN).
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Western blot analysis
Cell pellets were lysed in buffer containing 50 mM Tris pH 8.0, 5 mM EDTA, 0.5% NP40
and 100 mM sodium chloride for 20 minutes at 4 C.  Protein concentration was
quantified using the Bradford Protein Assay (Bio-Rad, Berkeley, CA). The primary
antibodies used were: polyclonal AUF1 (Millipore, Billerica, MA, catalog number
07260MI) at 1:3000, polyclonal p-p38 (PhosphoSolutions, Aurora, CO, catalog number
p190-1802) at 1:1000, polyclonal p38 (Cell Signaling, Boston, MA, catalog number
9218) at 1:1000, monoclonal β-catenin (BD Biosciences, San Jose, CA, catalog number
610153) at 1:5000, and monoclonal α-tubulin (Abcam, Cambridge, MA, product number
ab6160) at 1:1000.  All secondary antibodies from the appropriate species were
horseradish peroxidase-conjugated (Jackson Laboratories, Bar Harbor, ME) and diluted
1:10000.
Virus Production
Virus was produced as described previously (23).
RNA-binding protein immunoprecipitation (RIP)
Cell pellets from 7x107 BJ fibroblasts were lysed in the same buffer used for western
blot analysis.  Protein concentration was analyzed using the Bradford Protein Assay
(Bio-Rad, Berkeley, CA).  Three mg of protein was used for each immunoprecipitation.
The following primary antibody was used: 30 μg of polyclonal AUF1 (Millipore, Billerica,
MA, catalog number 07260MI).  Equivalent amounts of normal IgG antibody (Cell
Signaling, Boston, MA) were used to control for specific immunoprecipitation.  Cell
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lysates were pre-cleared with 20 μL protein A Dynabeads (Life Technologies, Carlsbad,
CA) for 30 minutes at 4 C prior to immunoprecipitation.  100 μL Protein A Dynabeads
were used for each immunoprecipitation.  Beads were washed 3 times in 0.1 M
monosodium phosphate and then incubated in 0.1 M monosodium phosphate with the
appropriate antibody for at least 1 hour at room temperature.  Beads were then washed
3 times in Buffer A (1x PBS, 0.1% SDS, 0.3% sodium deoxycholate, 0.3% NP40),
followed by incubation for 30 minutes at room temperature in NT2 buffer (50 mM Tris
pH 7.4, 150 mM sodium chloride, 1 mM magnesium chloride).  Antibody-bound beads
were then added to pre-cleared cell lysates, and immunoprecipitated overnight at 4 C.
100 μL of cell lysate was removed from the IgG immunoprecipitation to be used for input
controls.  Immunoprecipitated beads were washed 2 times with each of the following
buffers: Buffer A, Buffer B (5x PBS, 0.1% SDS, 0.5% sodium deoxycholate, 0.5% NP40)
and Buffer C  (50 mM Tris pH 7.4, 10 mM magnesium chloride, 0.5% NP40).  Beads
were then resuspended in NT2 containing 0.1% SDS, 80 U RNase OUT (Life
Technologies, Carlsbad, CA), and 30 μg Proteinase K and incubated at 55 C for 30
minutes.  RNA was isolated from the beads by adding 1 mL of TRI Reagent (Life
Technologies, Carlsbad, CA).  Following cDNA synthesis, mRNA levels of SASP factors
were analyzed by qPCR using the primers and procedures described above.
Luciferase reporter assay
BJ fibroblasts were transiently transfected with plasmids encoding NFκB-luc and Renilla
luciferase. Renilla luciferase expression was used to standardize for transfection
efficiency. Transfection was performed using manufacturer’s protocol for the
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Lipofectamine 2000 reagent (Life Technologies, Carlsbad, CA).  Luciferase activities
were measured 48 hours post-transfection using live cell imaging as described (43).
Co-culture
Co-culture experiments were performed as previously described with the following
modifications (23).  1.3×104 fibroblasts were plated in black-walled 96 well plates
(Fisher Scientific, Pittsburgh, PA). Cells were incubated in starve medium (DMEM + 1%
penicllin/streptomycin) for 3 days before the addition of HaCat-CBR cells. SB203580
was refreshed daily until HaCaT-CBR plating. HaCat-CBR cells were cultured in starve
medium for 24 hours prior to plating on fibroblasts. 1.0×103 HaCat-CBR cells were
plated on fibroblasts and incubated for the indicated length of time.  At the times
indicated, D-luciferin (Biosynth, Naperville, IL) was added to a final concentration of 150
μg/mL.  After ten minutes, plates were imaged using an IVIS 100 camera (PerkinElmer,
Downers Grove, IL) using the following settings: exposure=10 s–5 min, field of view=15,
binning=16, f/stop=1, open filter.
Xenografts
1x106 BPH1-CBR preneoplastic prostate epithelial cells were co-injected with 1x106 BJ
human foreskin fibroblasts. Cells were injected subcutaneously in a 50:50 mixture of
DMEM:growth factor-reduced Matrigel (BD Biosciences, San Jose, CA) into the rear
flanks of female NcR nude mice (Taconic, Germantown, NY). In vivo bioluminescence
imaging was performed on the days indicated on an IVIS 100 (PerkinElmer, Downers
Grove, IL; Living Image 3.2, 1–60 s exposures, binning 4, 8 or, 16, FOV 15 cm, f/stop 1,
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open filter) following IP injection of D-luciferin (150 mg/kg; Biosynth, Naperville, IL). For
analysis, total photon flux (photons/sec) was measured from a fixed region of interest
over the xenografts using Living Image 2.6 (PerkinElmer, Downers Grove, IL).
RNA Sequence Analysis
Total RNA was isolated using TRI Reagent (Life Technologies, Carlsbad, CA) and the
RiboPure RNA isolation kit (Life Technologies, Carlsbad, CA) following the
manufacturer’s instructions. Ribosomal RNA was removed by poly-A selection using
oligo-dT beads. mRNA was then fragmented and reverse transcribed to yield double
stranded cDNA using random hexamers. cDNA was blunt ended, had an A base added
to the 3’ ends, and then had Illumina sequencing adapters ligated to the ends. Ligated
fragments were then amplified for 12 cycles using primers incorporating unique index
tags. Fragments were sequenced on an Illumina HiSeq-2000 (San Diego, CA) using
single reads extending 50 bases. Raw data was de-multiplexed and aligned to the
reference genome using TopHat.  Transcript abundances were then estimated from the
alignment files using Cufflinks. EdgeR was used for differential expression analysis.
Generation of CAFs
Primary breast tissue was collected without patient identifiers in compliance with a
protocol approved by the Brigham and Women’s Hospital (Institutional Review Board
93-085).  Fibroblasts were isolated (10, 11) and immortalized through expression of
hTERT-GFP (44) as previously described.
88
To generate cancer-associated fibroblasts (CAFs), 3x106 human mammary fibroblasts
were co-injected with 1x106 MCF7-Ras tumor cells subcutaneously into nude mice.
After tumors reached 1 cm, mice were euthanized and CAFs were re-isolated by
digesting tissues in 1 mg/ml collagenase A for 1-4 hours at 37 °C with continuous
rotation.  Resulting cell suspensions were dispersed with an 18-gauge needle, washed
2 times with resuspension buffer (2% heat-inactivated fetal calf serum in sterile Hank’s
Balanced Salt Solution (HBSS)), and filtered through 70 m nylon mesh.  GFP+ CAFs
were then isolated by fluorescence-activated cell sorting and maintained under their
standard culture conditions. CAFs were confirmed to be human by staining with human
specific mitochondrial DNA (data not shown).
Oral dosage of p38MAPK inhibitor
The p38MAPK small molecule inhibitor CDD-111 (Confluence Life Sciences, Inc, St.
Louis, MO) was compounded at 516 ppm with Purina Rodent Chow #5001 (St. Louis,
MO) to generate a daily exposure of 80 mg/kg/day.  Female NcR nude mice (Taconic,
Germantown, NY) were fed ad libitum.
LPS challenge and TNFα ELISA
Female NcR nude mice (Taconic, Germantown, NY) were fed ad libitum for 3 days. 100
ng lipopolysaccharide (LPS) (Sigma, St. Louis, MO) was then administered by IP
injection.  Serum was collected 1 hour after LPS dosage.  TNFα levels were analyzed
by ELISA (R&D Systems, Minneapolis, MN)
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Staining of xenograft tumors
Following excision, tumors were fixed in 10% formalin and embedded in paraffin for
sectioning.  Standard H&E technique was used for all sections.  Serial sections were
stained for Ki67 (1:50, catalog number 550609, BD Bioscience, San Jose, CA), p16
(1:100, catalog number sc-1661, Santa Cruz Biotechnology, Dallas, TX) and vimentin
(1:700, catalog number ab45939, Abcam, Cambridge, MA).
Statistical Analysis
Data is presented as the mean ± SEM. Statistical significance was determined using the
Student’s t test, with a p value < 0.05 considered significant.  Percent mRNA remaining
was calculated as the fold mRNA in ActD-treated SIPS cells over untreated SIPS cells.
Overrepresented gene ontology terms in the expression data were identified using a
Fisher’s exact test, with a significance threshold of p < 0.05 as implemented in GOstat
(45).
RESULTS
p38MAPK activity controls the pro-tumorigenic properties of the SASP
SASP factors promote preneoplastic cell growth (6-8, 23, 24) and p38MAPK contributes
significantly to the initiation of SASP factor expression (25). To confirm this, senescent
fibroblasts (fibroblasts staining positive for senescence-associated β-gal, Supplemental
Fig. 3.1A) were treated with a highly specific small-molecule inhibitor of p38MAPK
(SB203580) (26).  Hsp27 is a direct downstream target of p38MAPK.  Therefore, to
confirm that our treatment inhibited the kinase activity of p38MAPK, we measured
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Hsp27 phosphorylation by Western blot analysis.  We found that SB203580 treatment
led to a reduction in Hsp27 phosphorylation, indicating successful inhibition of
p38MAPK activity (Fig. 3.1A).  As expected, SB203580 treatment of senescent
fibroblasts resulted in a significant reduction in the expression of SASP factors IL6, IL8,
and GMCSF (Fig. 3.1B).  To determine if p38MAPK activity was responsible for the
tumor-promoting activities of senescent cells, we performed co-culture experiments with
normal human fibroblasts induced to senesce by treatment with bleomycin (referred to
throughout as stress-induced premature senescence, SIPS) and preneoplastic HaCaT
keratinocyte cells expressing click beetle red (CBR) luciferase (HaCaT-CBR) (23).  Prior
to the addition of HaCAT-CBR cells, fibroblasts were treated with vehicle or SB203580
as indicated in Fig. 3.1C.  Senescent fibroblasts treated with vehicle increased the
growth of HaCaT-CBR cells compared to HaCaT-CBR cells cultured with young
fibroblasts (Fig. 3.1D), recapitulating our previously published observations (15, 23).
However, while inhibition of p38MAPK had no effect on HaCAT-CBR cells grown in the
absence of fibroblasts (Supplemental Fig. 3.1B), we found that p38MAPK inhibition
reduced the pro-tumorigenic activity of senescent fibroblasts by significantly reducing
HaCaT-CBR cell growth (Fig. 3.1D).
Given the potent impact of p38MAPK inhibition in co-culture experiments, we next
examined the impact of p38MAPK depletion on preneoplastic cell growth in xenograft
experiments.  P38MAPK was depleted from senescent fibroblasts (Fig. 3.1E), resulting
in a significant reduction in the level of p38MAPK-dependent SASP factor IL8 (Fig.
3.1F). To assess the impact of p38MAPK loss in vivo, young, senescent, or p38MAPK-
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depleted senescent fibroblasts were admixed with the preneoplastic epithelial cell line
BPH1 expressing CBR luciferase (BPH1-CBR) and injected subcutaneously into nude
mice.  Tumor growth was analyzed by bioluminescence imaging.  As expected,
senescent fibroblasts increased BPH1-CBR cell growth relative to young fibroblasts
(Fig. 3.1G).  However, depletion of p38MAPK and subsequent reduction in p38MAPK-
dependent SASP factor expression reduced tumor growth to the level observed when
BPH1-CBR cells were co-injected with young fibroblasts (Fig. 3.1G).  These results
indicate that expression of p38MAPK-dependent SASP factors within the TME plays a
pivotal role in preneoplastic cell growth in vivo.
The pro-tumorigenic SASP is subject to post-transcriptional regulation
We next sought to elucidate the mechanism by which p38MAPK regulates pro-
tumorigenic SASP factor expression.  Previous work demonstrated that p38MAPK
modulates NFκB-driven transcription of SASP factors including IL6 and IL8 (19).  To
determine that the effects of p38MAPK inhibition were transcriptionally based,
senescent fibroblasts were treated with the transcription inhibitor actinomycin D (ActD)
at several time points following bleomycin treatment.  SASP factor expression was
significantly inhibited when cells were treated with ActD 24 hours after bleomycin
treatment (Fig. 3.2A), a time point at which SASP factor mRNA was increased
(Supplemental Fig. 3.2A), but cells were not yet senescent (Supplemental Fig. 3.1A).
These results indicate that at this time point SASP factor expression is dependent on
transcription. Surprisingly, at 96 hours after bleomycin treatment, when cells displayed
morphological features characteristic of senescence including staining positive for SA-β-
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gal (Supplemental Fig. 3.1A), treatment with ActD failed to reduce SASP factor mRNA
levels (Fig. 3.2A).  These changes in mRNA were also reflected at the protein level.
Indeed, we found that IL6 protein levels in conditioned medium collected from cells
treated with ActD at 24 hours fell drastically compared to untreated cells.  In contrast,
when cells were treated with ActD at 96 hours, IL6 protein levels remained high (Fig.
3.2B).  Given p38MAPK inhibition at the later time point significantly reduced SASP
expression (Fig. 3.1B), these findings raised the possibility that p38MAPK impacts
SASP factor mRNA stability rather than NFκB-driven transcriptional activation upon the
acquisition of senescence.  To confirm that p38MAPK had no effect on NFκB-driven
transcription at the later time point, normal human fibroblasts were transduced with an
NFκB transcription reporter plasmid driving expression of luciferase (NFκB-luc).
Transduced cells were treated with bleomycin, and 72 hours later senescent cells were
treated with the p38MAPK inhibitor SB203580 for an additional 48 hours.  As expected,
when SB203580 treatment was initiated 72 hours after bleomycin treatment, there was
no significant effect on NFκB transcriptional activity (Fig. 3.2C). These results indicate
that after the establishment of senescence, p38MAPK has a profound effect on SASP
factor mRNA stability.
To address whether SASP factor mRNA stability was affected in cells undergoing
replicative senescence or other types of stress-induced senescence, normal human
fibroblasts were induced to senesce through telomere dysfunction (replicative
senescence, RS) or treatment with the histone deacetylase inhibitor sodium butyrate
(NaB).  Cells undergoing RS or NaB-induced senescence robustly induced expression
93
of SASP factors, including IL6 and IL8 (Supplemental Fig. 3.2B and Supplemental
Fig. 3.2C, respectively).  Further, we found that SASP factor mRNAs were significantly
stabilized in cells that had undergone RS or NaB-induced senescence (Fig. 3.2D and
Supplemental Fig. 3.2D, respectively).  Significantly, SASP factor mRNA stabilization
was not limited to skin fibroblasts; when IMR90 human lung fibroblasts were treated
with bleomycin, they displayed a similar increase in SASP factor mRNA stability 96
hours post-bleomycin treatment (Supplemental Fig. 3.2E). Together, these data
indicate that SASP factor mRNAs are stabilized by a post-transcriptional regulatory
program that is active in fibroblasts from diverse tissues, regardless of the mechanism
through which senescence is induced.
p38MAPK post-transcriptionally regulates the SASP
Our results indicate that p38MAPK inhibition reduces SASP expression and TME-
dependent promotion of tumorigenesis but does not affect the activity of the primary
transcriptional regulator of the SASP, NFκB, following induction of senescence.
Interestingly, p38MAPK post-transcriptionally regulates IL6 and IL8 in other contexts
(20, 21). Thus, we investigated p38MAPK’s role in stabilizing SASP factor mRNA. We
first examined whether p38MAPK was active throughout the time course under
investigation. To assess p38MAPK activation, lysates were prepared from cells 24 or
96 hours after bleomycin treatment and examined for phosphorylated p38MAPK (p-p38)
by Western blot analysis. In agreement with previous findings (19), we observed that
phosphorylated p38MAPK increased from 24 to 96 hours following bleomycin treatment
(Supplemental Fig. 3.2F).  These kinetics were consistent with SASP factor mRNA
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stabilization, suggesting that p38MAPK activation regulates SASP factor mRNA
stability.
To elucidate p38MAPK’s role in regulating SASP factor mRNA stabilization, normal
human fibroblasts depleted of p38MAPK (shp38) were treated with ActD 24 or 96 hours
after bleomycin treatment (Fig. 3.2E). When treated with ActD 24 hours after bleomycin
treatment, cells expressing shSCR or shp38 displayed decreased SASP mRNA
stability, indicating that p38MAPK does not post-transcriptionally regulate SASP mRNAs
at this time point.  As expected, both IL6 and IL8 mRNA stability increased when shSCR
control cells were treated with ActD 96 hours after bleomycin treatment, although not to
the same extent as that observed in non-transduced fibroblasts.  In contrast, when
shp38 cells were treated with ActD 96 hours post-bleomycin treatment, they displayed
significantly reduced IL6 and IL8 mRNA stability when compared to cells expressing the
control hairpin (shSCR) (Fig. 3.2E). Similar results were obtained with a second
independent shRNA targeting p38MAPK (data not shown).
The 3’ UTRs of SASP factor transcripts control mRNA stabilization in stromal
cells
We next examined the mechanisms by which SASP factor mRNA was stabilized. The
3’ untranslated region (UTR) of many mRNAs contains protein binding motifs that alter
mRNA stability under diverse biological stimuli (27). To determine whether the 3’ UTRs
of SASP factor mRNAs govern post-transcriptional regulation, we utilized a luciferase
reporter cDNA fused to the 3’ UTR of IL6 (lucIL6) or GMCSF (lucGMCSF). A luciferase
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reporter cDNA fused to the 3’ UTR of GAPDH (lucGAP) was used as a control. Normal
human fibroblasts were stably transduced with the luciferase reporter constructs and
luciferase mRNA levels were monitored in response to ActD at the time points indicated
(Fig. 3.3A). Similar to our observations with the endogenous IL6 and GMCSF
transcripts, we observed that the stability of the lucIL6 and lucGMCSF transcripts
increased significantly when treated with ActD 96 hours compared to 24 hours after
bleomycin treatment (Fig. 3.3A). As expected, there was no significant change in the
stability of the lucGAP transcript (Fig. 3.3A), indicating that 3’ UTR-dependent mRNA
stabilization was specific for SASP factor mRNA and did not extend to all mRNAs in
response to senescence. These results indicate that the 3’ UTR of SASP factor
transcripts mediates increases in mRNA stability.
AUF1 directly binds to SASP factor mRNA and modulates their stabilization
AUF1 is a protein that binds the 3’ UTRs of many mRNAs including IL6, IL8, and
GMCSF and reduces their stability (28-30).  Furthermore, p38MAPK is known to impact
AUF1 activity in other settings (22), although a link between AUF1 and p38MAPK in the
post-transcriptional regulation of IL6 and IL8 has not been demonstrated. To examine
AUF1 binding to SASP factor mRNA in response to senescence, we utilized RNA-
binding protein immunoprecipitation (RIP) to examine AUF1 binding to SASP factor
mRNAs in response to senescence.  Cell lysates were collected 24 and 96 hours after
bleomycin treatment and subjected to immunoprecipitation with either an AUF1-specific
antibody or a nonspecific IgG; mRNA levels were normalized to the levels of each
transcript measured in the input fractions. We observed that AUF1 occupancy on IL6
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and IL8 mRNAs significantly decreased from 24 to 96 hours after bleomycin treatment
(Fig. 3.3B), corresponding with the increase in mRNA stability observed in Fig. 3.2. We
observed similar results for GMCSF and CCL20 mRNA, indicating that this mechanism
impacts many SASP factor mRNAs (Fig. 3.3B). This observation suggests that
decreased AUF1 binding leads to increased mRNA stability once senescence is
established.
We next sought to determine whether AUF1 was required to destabilize SASP mRNAs.
To address this question, we stably transduced normal human fibroblasts with two
independent short-hairpin RNA (shRNA) constructs targeting AUF1 (shAUF1a and
shAUF1b) (Fig. 3.3C).  AUF1-depleted cells were treated with bleomycin and 24 hours
later treated with ActD, a time at which AUF1 is bound to SASP factor mRNAs
displaying reduced stability (Fig. 3.3B).  In contrast to control cells, we found that AUF1
depletion significantly increased the stability of IL6 and IL8 mRNA at the early time point
when these mRNAs are normally unstable (Fig. 3.3D).  These data demonstrate that
before senescence is established, AUF1 destabilizes SASP mRNAs by binding to their
3’ UTRs.
To address whether the impact of p38MAPK on SASP mRNA stabilization was due to
modulation of AUF1–SASP mRNA binding, we carried out RIP analysis. Following
bleomycin treatment, normal human fibroblasts were treated with SB203580 or vehicle
control as described in Fig. 3.3E. In contrast to control cells in which AUF1 occupancy
decreased at the late time point, there was no decrease in AUF1 occupancy on IL8
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mRNA in p38MAPK-inhibited cells collected 96 hours after bleomycin treatment (Fig.
3.3E). Similar results were obtained for IL6 (data not shown). These observations
indicate that p38MAPK activation is required to release AUF1 from SASP factor mRNA.
Further, these studies suggest that loss of SASP factor mRNA stabilization in p38MAPK
inhibited cells (Fig. 3.2) is the result of a failure to remove AUF1 from SASP factor
transcripts.
p38MAPK-dependent factors are expressed in the TME of breast cancer lesions
The TME plays a pivotal role in tumor progression, and recent expression analyses
indicate that TME-specific expression changes are predictive of clinical outcome (1-3).
Both senescent fibroblasts and CAFs express pro-tumorigenic SASP factors, raising the
intriguing possibility that the regulatory mechanisms that control SASP expression in
senescent cells also operate in cancer-associated stroma.  Given the importance of
p38MAPK in SASP factor expression, we carried out a meta-analysis to establish a list
of p38MAPK-regulated genes in senescent fibroblasts and evaluated their expression in
the TME of human breast cancers (Fig. 3.4A).  We performed RNA sequence analysis
(RNA-seq) of young, senescent, and p38MAPK-inhibited senescent human fibroblasts
and observed that IL6 and IL8 expression was p38MAPK-dependent.  Along with
previously identified factors, we found that 50 additional SASP factors were p38MAPK-
dependent, including GMCSF, GCSF, IL1α, IL1β, CXCL1, CXCL2, CXCL5, CCL20,
MMP1, and MMP7 (Supplemental Table 3.1, Fig. 3.4A).  A subset of these factors was
validated by qRT-PCR (Supplemental Fig. 3.3A). Gene ontology (GO) process
analysis performed on the p38MAPK-dependent factors demonstrated that genes
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related to the regulation of inflammation, chemotaxis, cell adhesion, angiogenesis, and
proliferation were significantly enriched in this gene set (Fig. 3.4B).
We next compared our p38MAPK-dependent SASP list to factors significantly over-
expressed in the TME of breast cancer (BC) lesions.  We examined three data sets
generated from microarray analyses of normal stroma versus cancer-associated stroma
that had been obtained by laser capture micro-dissection of breast tissue (1-3) (Fig.
3.4A).  Of the 50 p38MAPK-dependent factors identified in senescent fibroblasts, we
found that 29 were expressed in the stroma of the Finak breast cancer dataset (1),
including CXCL2 and IL24.  Seventeen factors were expressed in the TME of the Ma
breast cancer data set (2), including IL1β.  Finally, 7 factors overlapped with the
Karnoub breast cancer data set (3), including CCL20 (Supplemental Table 3.1).
Furthermore, CCL20, CXCL5, IL11, IL1β, IRAK3, MMP1, MPP7, and SOD2 were
expressed in the BC-associated stromal compartment of at least two studies (Fig.
3.4C).  Of note, CCL20, CXCL5, IL11, IL1β, and MMP1 are factors with known pro-
tumorigenic activities (31-35). We observed that BC-associated stromal genes
compose a large percentage of the total number of p38MAPK-dependent SASP factors
involved in the regulation of inflammation, chemotaxis, angiogenesis, and cell adhesion
based on GO process analyses (Fig. 3.4B).  Given that these factors are associated
with disease progression, our findings raise the possibility that anti-p38MAPK therapy
could significantly impact tumor progression in humans.
Inhibition of p38MAPK abrogates the pro-tumorigenic activities of CAFs
99
Expression of p38MAPK-dependent factors within the stroma of breast cancer lesions
raised the possibility that they contribute to the tumor promoting activities of CAFs.
Therefore, we examined whether inhibition of p38MAPK would abrogate the tumor-
promoting activities of CAFs as it did for senescent fibroblasts.  To generate CAFs, we
obtained normal human mammary fibroblasts from reduction mammoplasty (NMF),
admixed them with MCF7-Ras breast carcinoma cells and injected the cell mixture into
immunocompromised mice and allowed tumors to grow.  Human CAFs were isolated
from these tumors and we assessed their tumor-promoting potential by co-culturing
them with preneoplastic HaCaT skin keratinocytes expressing CBR luciferase (HaCaT-
CBR). As expected, CAFs significantly stimulated HaCaT-CBR cell growth compared to
HaCaT-CBR cells cultured with parental NMF fibroblasts (Fig. 3.4D).  To investigate the
importance of p38MAPK-dependent CAF factors, we inhibited p38MAPK in CAFs with
SB203580 and assessed their ability to promote preneoplastic cell growth.  Similar to
what we observed when senescent fibroblasts were treated with the p38MAPK inhibitor
SB203580 (Fig. 3.1C), CAFs treated with SB203580 failed to promote HaCaT-CBR cell
growth (Fig. 3.4D).  These results indicate that p38MAPK regulates the tumor-
promoting activity of CAFs.  Together with our meta-analysis and expression of
p38MAPK-dependent genes in the stromal compartment of human breast cancer
lesions, these observations suggest that p38MAPK plays a central role in sustaining the
expression of tumor-promoting factors.  Thus, stromal p38MAPK represents a novel
therapeutic target for senescent and non-senescent cancer-associated stromal
compartments in breast cancer.
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p38MAPK inhibition compromises the tumor-promoting capacity of the
microenvironment
The critical importance of SASP factor expression in our tumor models and our work to
uncover the mechanisms that sustain SASP factor expression identified p38MAPK as a
central player in SASP expression in senescent cells as well as in CAFs.  Given our
findings that p38MAPK-dependent factors are expressed in human breast cancer
lesions, we evaluated the feasibility of targeting p38MAPK in a preventative and
therapeutic setting.  Several p38MAPK inhibitors have entered phase II clinical trails for
rheumatoid arthritis and thus have proven safe in a nonlethal disease (36, 37). We
obtained a p38MAPK inhibitor (CDD-111, also referred to as SD-0006 (38), Confluence
Life Sciences) and compounded it into mouse chow.  CDD-111 was chosen because it
can be orally administered and shows high specificity for the p38MAPK α subunit (38).
Indeed, extensive analysis of CDD-111 revealed that it is selective for p38MAPK α over
fifty other kinases including p38MAPK β, γ, and δ.  Furthermore, the IC50 for inhibiting
tumor necrosis factor-α (TNFα) release in vitro and in vivo was less than 200 nM (38).
Treatment of senescent cells with CDD-111 in vitro revealed that it effectively reduced
SASP expression as evidenced by a significant reduction in IL6 and IL8 levels (data not
shown).
To establish the impact of orally administered CDD-111 on p38MAPK activity in our
system, mice were placed on CDD-111 (p38i) or control chow for three days,
challenged with LPS, and serum TNFα levels were measured.  We found that mice
receiving oral p38i failed to mount a robust TNFα response following an LPS challenge
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compared to animals receiving control chow (Supplemental Fig. 3.3B).  We also
verified that p38i inhibited SASP expression in vivo.  Senescent normal human
fibroblasts were injected subcutaneously into the rear flanks of nude mice maintained
on control or p38i chow.  Ten days after injection the cells were removed, RNA was
isolated, and the levels of human IL8 were analyzed by qRT-PCR.  Senescent
fibroblasts isolated from mice on p38i had significantly less IL8 mRNA than senescent
fibroblasts isolated from mice on control chow (Fig. 3E), demonstrating that CDD-111
inhibited SASP expression in vivo.
We next evaluated the p38MAPK inhibitor’s efficacy in a xenograft setting.  BPH1-CBR
cells admixed with young or senescent fibroblasts were subcutaneously injected into
mice maintained on control or p38i chow (Fig. 3.4F).  Bioluminescence analysis of
tumor growth revealed that p38i significantly reduced the growth of BPH1-CBR cells co-
injected with senescent fibroblasts (Fig. 3.4G & H).  Analysis of cellular proliferation
(Ki67 staining) revealed that senescent fibroblasts significantly increased BPH1 cell
proliferation compared to when BPH1 cells were co-injected with young fibroblasts (Fig.
3.5A).  Importantly, the increase BPH1 proliferation that was noted in the presence of
senescent fibroblasts was markedly reduced when mice were maintained on p38i
versus control chow (Fig. 3.5A). These data demonstrate that the reduced tumor size
observed in response to p38i administration was a result of decreased epithelial cell
proliferation.  Importantly, the difference in epithelial cell proliferation between tumors
containing senescent stroma from p38i- and control-fed mice was not due to differences
in stromal composition between these tumor types, as staining for a senescence
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marker, p16, and a fibroblast marker, vimentin, demonstrated that 1) senescent
fibroblasts persisted throughout the time course of the experiment regardless of
p38MAPK inhibition and 2) the stromal composition of treated and untreated tumors
was similar.  Vascularity and myeloid infiltration were also investigated in these tumors.
No significant differences in either vascularity or leukocyte infiltration were noted (data
not shown).  Administration of CDD-111 to mice injected with BPH1 cells admixed with
young fibroblasts also resulted in a decrease in epithelial cell growth, although not to the
same extent as that observed in tumors containing senescent fibroblasts.  Oral
administration of CDD-111 had no significant impact on BPH1-CBR cells injected alone
(data not shown).
To address the effectiveness of p38MAPK inhibition in a therapeutic setting, mice were
injected with BPH1-CBR cells admixed with senescent fibroblasts and tumors were
allowed to grow for one week until the average tumor volume reached 74 mm3.  Mice
were then administered control or p38i chow and bioluminescence imaging was used to
monitor tumor growth. Significantly, tumor growth was arrested in mice receiving p38i.
In contrast, tumors in mice receiving control chow continued to show significant growth
(Fig. 3.5B).
To investigate the applicability of orally administered p38i in CAF-containing
microenvironments, we obtained primary CAFs (pCAFs) from a lesion removed from a
patient with invasive breast cancer.  We subcutaneously injected BPH1 cells alone or
BPH1 cells admixed with pCAFs into nude mice fed either control or p38i chow as
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described for the experiments in Fig. 3.4F.  As expected, there was no difference in
BPH1 cell growth whether mice were fed control or p38i chow (Fig. 3.5C).  Importantly,
in mice receiving control chow, BPH1 cells admixed with pCAFs grew significantly more
than BPH1 cells injected alone, verifying that our patient-derived fibroblasts were bona
fide CAFs (Fig. 3.5C).  pCAF-mediated BPH1 growth was significantly inhibited in mice
receiving p38i (Fig. 3.5C), similar to what was observed with senescent fibroblast-
mediated BPH1 growth (Fig. 3.4G and H). These findings, combined with those from
p38MAPK inhibition of senescent-fibroblast driven tumors, suggest that p38MAPK is a
viable, stromal specific therapeutic target that may show efficacy in diverse tumor
microenvironments and diverse tumor types
DISCUSSION
The regulation of SASP expression is complex, involving the DNA damage response
(16), HDAC1 activity (15), and transcriptional regulation by NFκB and C/EBPβ (17-19).
p38MAPK perhaps best exemplifies the complexity of SASP regulation.  Previous
reports have shown that p38MAPK impacts NFκB-driven transcriptional control of SASP
expression immediately following exposure to a senescence-inducing signal (19).  In our
system, p38MAPK inhibition had no effect on NFκB transcriptional activity when it was
initiated after cells acquired the senescent phenotype as evidenced by SA-β-gal
staining.  However, p38MAPK inhibition did have a significant impact on SASP factor
mRNA stability.  Our data are consistent with p38MAPK playing a dual role in SASP
factor expression.  We hypothesize that SASP factor expression is achieved through
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early rounds of transcription followed by post-transcriptional mRNA stabilization, both of
which require distinct p38MAPK functions.
Inhibiting the SASP represents a novel stromal-specific therapeutic cancer modality that
could be beneficial at multiple stages of tumorigenesis.  We have demonstrated that
senescent cells are present in the microenvironment before the formation of
preneoplastic lesions and that SASP factors promote preneoplastic cell growth (15, 23).
The SASP also promotes more aggressive malignancies by increasing angiogenesis
and invasion (9, 39).  Finally, the SASP is hypothesized to promote later events in
cancer progression including metastasis and recurrence through its promotion of cancer
stem cell formation and chemo-resistant niches (7, 40, 41).  Together, these findings
suggest that inhibition of the SASP will prevent the development and/or progression of
malignancies.  p38MAPK could provide an ideal target as it impacts both the
transcriptional and post-transcriptional regulation of SASP (19) and may be particularly
effective because it can inhibit SASP expression after the stabilization of SASP mRNAs
has already occurred.
Our findings that oral administration of a p38MAPK inhibitor dramatically inhibits SASP-
mediated tumor growth driven by senescent fibroblasts and CAFs indicates for the first
time that the tumor-promoting capabilities of senescent and cancer-associated
fibroblasts are mediated through similar signaling pathways.  Furthermore, these
findings suggest that p38MAPK is an important therapeutic target with wide applicability
in a variety of tumor-promoting microenvironments.  This is strengthened by our in silico
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analysis of the stromal compartment of breast cancer lesions, which we show express
many p38MAPK-dependent genes.  These data are intriguing in light of the fact that
p38MAPK inhibitors have moved into phase II and III clinical trials for inflammatory
diseases including rheumatoid arthritis, Crohn’s disease, and psoriasis, demonstrating
their tolerability in patients (36, 37).  Given our findings, we suggest that p38MAPK
inhibitors warrant investigation for use as anti-neoplastic therapy.
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Fig. 3.1: p38MAPK activity controls the pro-tumorigenic properties of the SASP A)
Western blot analysis demonstrating that SB203580 treatment inhibits p38MAPK
activity. SB203580 treatment significantly impacts phosphorylation of p38MAPK’s direct
downstream target, Hsp27. B) Schematic of protocol to generate SIPS in BJ fibroblasts.
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Cells were treated with bleomycin for 24 hours.  SB203580 (SB) treatment or vehicle
control was initiated 48 hours after removal of bleomycin (bleo).  96 hours after
bleomycin treatment, cells were collected for expression analysis of IL6, IL8, and
GMCSF by qRT-PCR. Representative experiment, n=4. C) Timeline of bleomycin (bleo)
and SB203580 treatment of BJ fibroblasts in (D).  SB203580 was replenished daily until
co-culture with HaCAT-CBR cells was initiated. D) Growth of human keratinocytes
expressing click beetle red (HaCaT-CBR) measured 8 days following initiation of co-
culture with indicated fibroblast populations. Representative experiment, n=3. E) BJ
fibroblasts were depleted of p38MAPK through the expression of shRNA (shp38) or
control shRNA (shSCR). p38 depletion was verified by western blot analysis. F)
Expression of IL8 was analyzed by qRT-PCR 96 hours following bleomycin treatment in
p38MAPK-depleted (shp38) or control (shSCR) fibroblasts and represented relative to
young fibroblasts expressing shSCR control.  Representative experiment, n=3. G) BJ
fibroblasts expressing shp38 or shSCR were treated with bleomycin for 72 hours prior to
injection. Indicated fibroblast populations were admixed with preneoplastic epithelial
cells expressing click beetle red (BPH1-CBR cells) and injected subcutaneously into the
rear flanks of female NcR nude mice. Luciferase activity was measured using live,
whole-animal imaging to monitor BPH1 cell growth relative to baseline signal. Data
represents mean + SEM, n=8. Data represents mean + SD unless otherwise stated.  *
indicates p<0.05. SIPS: stress induced premature senescence.
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Fig. 3.2: p38MAPK post-transcriptionally regulates the SASP A) Schematic of
protocol to generate SIPS in BJ fibroblasts.  Cells were treated with bleomycin for 24
hours.  Cells were subsequently treated with actinomycin D (ActD) for 24 hours.  The
ActD treatment was initiated 24 or 96 hours after the completion of bleomycin treatment.
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IL6, IL8, GMCSF, and CCL20 mRNA levels were analyzed by qRT-PCR. To account
for changes in gene expression, levels mRNA in ActD-treated cells were normalized to
the levels observed in untreated cells from the respective time points (% mRNA
remaining). Representative experiment, n=3. B) ELISA analysis of IL6 protein levels in
conditioned media from cells treated as in (A). Representative experiment, n=4. C) BJ
fibroblasts were treated with bleomycin (bleo) for 24 hours and with SB203580 (SB) as
indicated. 96 hours post bleomycin treatment cells were transiently transfected with an
NFκB activity luciferase reporter. Luciferase activity was measured by live-cell imaging
48 hours post transfection. Representative experiment, n=2. D) Young BJ fibroblasts
(35 population doublings, PD) or replicatively senescent BJ fibroblasts (PD97) were
stained for senescence-associated β-galactosidase to confirm senescent phenotype
(left).  Cells were treated with ActD and IL6 mRNA levels were analyzed by qRT-PCR.
Representative experiment, n=3. E) BJ fibroblasts expressing a control hairpin (shSCR)
or shp38 were treated for 24 hours with ActD at 24 or 96 hours after the completion of
bleomycin treatment.  IL6 and IL8 mRNA levels were analyzed by qRT-PCR.
Representative experiment, n=2.
Data represent mean + SD.  * indicates p<0.05. SIPS: stress-induced premature
senescence.
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Fig. 3.3: AUF1 directly binds to SASP factor mRNA and modulates SASP factor
stabilization A) BJ fibroblasts were stably transduced with luciferase constructs fused
to the 3’ untranslated regions (UTR) of IL6, GMCSF, and GAPDH (lucIL6, lucGMCSF,
and lucGAP).  Cells were treated with ActD at 24 or 96 hours following bleomycin
treatment.  Luciferase mRNA levels were analyzed by qRT-PCR. Representative
experiment, n=3. B) RNA immunoprecipitation was performed for AUF1 using BJ
fibroblast cell lysates collected 24 or 96 hours after bleomycin treatment.  IL6, IL8,
GMCSF, and CCL20 mRNA levels in immunoprecipitations were analyzed by qRT-
PCR. Representative experiment, n=4. C) BJ fibroblasts were transduced with shRNAs
to deplete AUF1 (shAUF1A and shAUF1B) or a control shRNA (shSCR).  Protein levels
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were analyzed by western blot analysis. Note: there are four AUF1 isoforms present
and α-tubulin was used as a loading control. D) 24 hours following bleomycin treatment,
BJ fibroblasts expressing a control hairpin shSCR, shAUF1A, or shAUF1B were treated
with ActD for 1 hour. IL6 and IL8 mRNA levels were analyzed by qRT-PCR.
Representative experiment, n=2. E) RNA immunoprecipitation for AUF1 was performed
on BJ fibroblasts treated with bleomycin (bleo) and SB203580 (SB) as indicated.  The
level of IL8 mRNA in the AUF1 immunoprecipitation was measured by qRT-PCR.
Representative experiment, n=3. Data represent mean + SD. * indicates p<0.05.
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Fig. 3.4: p38MAPK-dependent factors are expressed in the TME of breast cancer
lesions A) RNA-seq analysis was performed on young fibroblasts, senescent
fibroblasts, and senescent fibroblasts treated with SB203580. RNA-seq results were
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analyzed to determine the number of factors upregulated in response to senescence
(SASP factors) and the number of p38MAPK-dependent factors. These results were
also analyzed for overlap with the expression profiles of breast cancer (BC)-associated
stroma. B) GO processes analysis was performed on p38MAPK-dependent SASP
factors. Results are presented as the percent of p38MAPK-depenedent genes assigned
to the processes shown. Black regions of the bars represent the percent of p38MAPK-
dependent SASP factors assigned to each process that are also expressed in BC-
associated stroma. The significance threshold was set at p < 0.05. C) p38MAPK-
dependent SASP factors that are expressed in more than one BC-associated stroma
data set. **indicates expression in 2 BC-associated stroma datasets, ***indicates
expression in 3 BC-associated stroma datasets. D) Tumor-educated human CAFs and
their normal isogenic counterparts (NMF) were treated with SB203580 (SB) or vehicle
as indicated and replenished daily until co-culture with HaCAT-CBR preneoplastic
keratinocytes was initiated. Luciferase activity was measured using live-cell imaging 4
days following initiation of co-culture to monitor HaCaT cell growth. Representative
experiment, n=2. E) Senescent BJ fibroblasts in matrigel were injected subcutaneously
into the rear flanks of nude mice fed either control or p38i chow.  Cells were removed 10
days after injection and IL8 mRNA levels were measured using qRT-PCR.
Representative experiment, n=4. F,G and H) Xenografts of BPH1-CBR cells co-injected
with senescent BJ fibroblasts (SIPS) into female NcR nude mice.  Control or the p38i
compounded chow were performed as outlined in (F).  Tumor are shown in (G).  Tumor
growth was analyzed by bioluminescence imaging (H). Data represent mean + SEM,
n=8.
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Data represent mean + SD unless otherwise stated. * indicates p<0.05. SIPS: stress
induced premature senescence.
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Fig. 3.5: p38MAPK inhibition is effective in both senescent fibroblast and CAF-
driven tumors A) Tumors were removed at the endpoint of the experiment described in
(Fig. 3.4F) and stained for Ki67 (dashed line demarks the margin between the mouse
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and xenograft), p16, and vimentin.  H&E images were captured with a 10X objective, all
other images were captured with a 20X objective.  Representative images, n=2. B)
Xenograft growth of BPH1-CBR cells co-injected with senescent BJ fibroblasts (SIPS)
into female NcR nude mice.  Tumors were allowed to grow for 1 week after injection, at
which time mice were placed on control or p38i-compounded chow.  Tumor growth was
analyzed by bioluminescence imaging.  Data represent mean + SEM, n=16. * indicates
significance between 1 and 3 weeks post-injection in mice fed control chow. C)
Xenografts of BPH1-CBR cells co-injected with pCAFs into female NcR nude mice.
Mice were fed control or p38i chow as outlined for the experiment in Fig. 3.4F.  Tumor
growth was analyzed by bioluminescence imaging.  Data represent mean + SEM, n is
indicated for each sample. * indicates p<0.05. NS: not significant.
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3.1:
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Supplemental Fig. 3.1: p38MAPK activity controls the pro-tumorigenic properties
of the SASP A) BJ fibroblasts were fixed for senescence-associated -galactosidase 24
or 96 hours after treatment with bleomycin. n=3. B) HaCAT-CBR preneoplastic skin
keratinocytes were treated with SB203580 or vehicle for 72 hours. Representative
experiment, n=3. Data is presented as mean  SD. * indicates p  0.05.
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Supplemental Fig. 3.2: p38MAPK post-transcriptionally regulates the SASP A) BJ
fibroblasts were treated with bleomycin for 24 hours. Cells were collected either 24 or
96 hours after treatment with bleomycin and upregulation of SASP factors IL6, IL8 and
GMCSF was verified by qRT-PCR. Representative experiment, n=3. B) BJ fibroblasts
were induced to senesce through telomere attrition (replicative senescence, RS).
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Upregulation of SASP factors IL6 and IL8 was verified by qRT-PCR. Representative
experiment, n=3. C) BJ fibroblasts were treated with sodium butyrate (NaB) for 120
hours. Upregulation of SASP factors IL6 and IL8 was verified by qRT-PCR.
Representative experiment, n=3. D) BJ fibroblasts were treated with NaB for 72 or 120
hours followed by actinomycin D (ActD) at the time points indicated. IL6 and IL8
expression was quantified by qRT-PCR. Representative experiment, n=3. E) IMR90
human lung fibroblasts were treated with bleomycin and ActD as described in Fig. 3.2B.
IL6 and IL8 expression was quantified by qRT-PCR. Representative experiment, n=2. F)
BJ fibroblast cell lysates 24 or 96 hours post bleomycin treatment were analyzed for
phosphorylation of p38MAPK (p-p38). Total p38MAPK was used as a loading control.
Representative experiment, n=3. Data is presented as mean + SD. * indicates p  0.05.
SIPS: stress-induced premature senescence.
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Supplemental Fig. 3.3: p38MAPK-dependent factors are expressed in the stromal
compartment of breast cancer lesions A) A subset of p38MAPK-dependent SASP
factors was validated by qRT-PCR in young, senescent or senescent fibroblasts treated
with SB203580. Data represent mean + SD. B) Female NcR nude mice were given
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control or p38i chow for 3 days prior to challenging with 100ng LPS. 1 hour post LPS
injection, mice were sacrificed and serum was collected for analysis by TNF ELISA.
Data represent mean + SEM, n=3. * indicates p  0.05. SIPS: stress-induced premature
senescence.
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Conclusions
Over the last decade, extensive research has greatly increased our understanding of
the SASP, its physiological and pathological roles, and its regulation.  It is now apparent
that the SASP is not a uniform, unchanging phenotype, but rather a complex response
to various stresses which is highly context-dependent.  The factors that make up the
SASP vary depending on the cell type, the senescence-inducer, and the environment.
Further, the magnitude of induction of individual factors is also dependent on the
context.
The complexity and variability of SASP induction is reflected by the complexity of the
regulatory networks which induce and restrain the many SASP factors.  This work
further illustrates that the SASP is not regulated by any single pathway, but rather by a
complex network of interrelated stress-responders, kinases, transcription factors,
mRNA-stability proteins, and other signaling and effector molecules.  The SASP is
initially upregulated via transcription, and multiple transcription factors are required to
induce the many SASP factors.  NF-κB and C/EBPβ are the canonical SASP-inducing
transcription factors, but many SASP-factors are upregulated independently of their
action (1–4).  Chapter Two of this dissertation focuses on understanding the regulation
of the SASP factor OPN. OPN was previously known to be independent of NF-κB in
response to senescence (4).  We identified C/EBPβ as a necessary regulator of OPN,
illustrating that while NF-κB and C/EBPβ regulate many of the same SASP factors, their
target gene sets are not identical (Fig 2.2).  Further, we showed that C/EBPβ directly
binds to the OPN promoter and that binding of exogenous LAP2, the full-length
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activating C/EBPβ isoform, increases at the OPN promoter as well as the promoters of
known C/EBPβ targets IL-6 and IL-8 (Fig 2.3).
Given the potent pro-tumor potential of senescent stromal-derived OPN, I sought to
understand how it was regulated in senescent fibroblasts.  Through this work, we
identified the novel SASP regulator c-Myb (Fig 2.4).  C-Myb binds to the OPN promoter
and this binding is required for promoter activation in response to senescence (Fig 2.5).
C-Myb also binds to the promoters of IL-6 and IL-8.  Further, using a combination of a
microarray and RNAi approach, I identified 59 additional putative c-Myb targets (Fig
2.6).  Of these 59 putative c-Myb targets, 47 were also putative C/EBPβ targets.  The
high degree of overlap between these two gene sets suggests that c-Myb and C/EBPβ
often co-regulate many SASP factors.  Although it has not been shown in this system, c-
Myb and C/EBPβ can directly interact and co-activate transcription, raising the
possibility that such a mechanism may be at play here (5). Given the importance of this
interaction in other systems, a key avenue of future research will be to explore whether
c-Myb and C/EBPβ interact directly in senescent cells, whether this interaction is
required for transcriptional activation of SASP factors, and how this interaction is
regulated.  Underscoring the importance of c-Myb and C/EBPβ for the induction of many
important SASP factors, I found that fibroblasts depleted of either c-Myb or C/EBPβ had
significantly reduced ability to promote preneoplastic epithelial cell growth in cocultures
(Fig 2.7).
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While transcription plays a critical role in the induction of SASP factors, post-
transcriptional stabilization of SASP factor mRNA is also important for the robust
induction of the SASP.  In Chapter 3, we identified this post-transcriptional regulatory
mechanism and described its importance for the induction of SASP factors including IL-
6, IL-8, and GM-CSF (Fig 3.2).  It is not known whether OPN is regulated in this
manner, as OPN mRNA is extremely stable at basal conditions, making it difficult to
assess whether it is further stabilized in senescent cells (6, 7). Interestingly, while
transcriptional induction of SASP mRNA occurs relatively quickly following exposure to
a senescence-inducing stimulus, the stabilization of SASP factor mRNAs occurs only
after the full establishment of cellular senescence days later.
The increase in the stability of many SASP factor mRNAs is dependent on p38MAPK
(Fig 3.2).  In response to senescence, p38MAPK is activated by phosphorylation and
plays at least two distinct roles in SASP factor induction.  First, p38MAPK is important
for the transcriptional induction of SASP factors via initiation of NF-κB activity (2).
Second, p38MAPK is required for the stabilization of SASP factor mRNAs in fully
senescent cells.  However, the transcription pathway is distinct from the post-
transcriptional stabilization pathway, and p38MAPK is not required for the continued
activity of NF-κB once senescence is fully established.  In fully senescent cells,
p38MAPK activity results in the removal of AUF1 from the 3’UTRs of SASP mRNAs
(Fig 3.3).  AUF1 is an mRNA destabilizing protein which binds to 3’-UTRs and causes
mRNA ubiquitination and degradation.
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Given the twofold nature of p38MAPK’s regulation of many important pro-tumorigenic
SASP factors, it is a promising potential therapeutic target.  We found that depletion or
inhibition of p38MAPK in senescent fibroblasts abrogates growth promotion of
preneoplastic epithelial cells by senescent fibroblasts in cocultures and xenograft
models (Figs 3.1).  Further, cancer-associated fibroblasts (CAFs) have a similar
expression profile to senescent fibroblasts and also promote growth of epithelial cells.
Treatment of CAFs with p38MAPK inhibitors inhibits their ability to promote the growth
of cocultured epithelial cells (Fig 3.4).  Furthermore, p38MAPK inhibitors are effective at
preventing the growth of established tumors growing in senescent fibroblast- or CAF-
supported microenvironments (Fig 3.5).  Many of the p38MAPK-dependent SASP
factors are present in human breast cancer patients’ stroma, suggesting that targeting
p38MAPK is a viable potential patient therapy (Fig 3.4).  The similarities between
senescent fibroblasts and CAFs in their expression profiles, shared regulation by
p38MAPK, and ability to promote epithelial cell growth underscore the notion that
senescent fibroblasts and CAFs are in essence two different types of activated
fibroblasts.
Future Directions
In Chapter 2, we established the transcription factor c-Myb as a regulator of a subset of
the SASP.  Further, we confirmed previous reports that C/EBPβ also regulates the
SASP, and we identified new SASP factor targets of C/EBPβ including OPN.  However,
the mechanism by which c-Myb and C/EBPβ regulate SASP factors remains
incompletely understood.  One important question is whether c-Myb and C/EBPβ are
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functioning independently to activate many of the same genes or whether they are
working in a coordinated fashion.  In other systems, c-Myb and C/EBPβ interact as a
heterocomplex between one c-Myb molecule and a C/EBPβ dimer (5).  It is not clear
whether c-Myb and C/EBPβ are interacting in our system, nor whether there is a
difference in the degree of interaction between non-senescent and senescent cells.  Co-
immunoprecipitations of c-Myb and C/EBPβ would help elucidate whether the genes are
interacting.  Further, we have synthesized a mutant form of C/EBPβ in which several of
the key residues in the c-Myb binding domain are mutated.  To test whether the putative
interaction between c-Myb and C/EBPβ is important, expression of this construct in an
endogenous C/EBPβ knockdown cell or mutation of the endogenous locus using
CRISPR/Cas9 would be followed by measurement of SASP factors such as OPN, IL-6,
and IL-8.  If the interaction is important, the SASP factor mRNA induction should be
inhibited.
While c-Myb and C/EBPβ both bind DNA separately, it is not clear whether this DNA
binding is required prior to the interaction between the two proteins, or if one or both of
the transcription factors can interact with and recruit the other protein to bind to the
DNA.  While there is no significant increase in c-Myb or C/EBPβ binding to the SASP
promoters we studied in response to senescence, exogenously expressed LAP2, a full
length isoform of C/EBPβ does increase binding in response to senescence. This
raises the possibility that in response to senescence there is a change in C/EBPβ
isoform binding to SASP promoters despite there being no change in overall C/EBPβ
binding. The isoforms derive from alternative translation initiation sites, and there are
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no available antibodies to carry out the needed ChIPs to answer this provocative
question, so alternative methods such as mass-spectrometry are needed.  This isoform
switch could facilitate activation of SASP genes if the inhibitory isoform LIP is replaced
by LAP2 or LAP1, both of which activate transcription.  If there is a change in C/EBPβ
isoform binding, a further question of interest is whether c-Myb facilitates or is
necessary for this switch.
Also of interest are the upstream activators of c-Myb and C/EBPβ.  C/EBPβ protein
levels increase in response to senescence (data not shown and ref. 3).  However, we
do not observe an increase in binding to SASP promoters. It has been reported that
ERK phosphorylates C/EBPβ in response to senescence.  This may activate C/EBPβ
and even drive interactions with c-Myb.  Likewise, c-Myb is subject to multiple post-
translational modifications, including phosphorylation, acetylation, and sumoylation (8–
12).  It remains to be seen if c-Myb is modified in response to senescence and whether
this modification is important for the activation of the SASP.
An additional question that remains unclear is whether p38MAPK regulates OPN in
response to senescence.  Preliminary data gave inconsistent results depending on the
means of p38MAPK depletion or inhibition, sometimes even yielding an increase in
OPN mRNA levels (data not shown).  P38MAPK regulates the SASP via a
transcriptional and a post-transcriptional mechanism and does so differentially
depending on the stage of senescence induction or maintenance.  This transition and
the importance of timing may explain the variable data.  Given that p38MAPK
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transcriptionally activates SASP factors via NF-κB, which does not regulate OPN in
senescence, it is unlikely that p38MAPK is required for transcriptional activation of OPN.
Further, OPN mRNA has a long half-life, and thus it is difficult to measure increases in
its stability (6, 7).  Nonetheless, it is possible that p38MAPK regulates OPN in response
to senescence.
Inhibiting p38MAPK does significantly reduce the induction of many SASP factors,
including IL-6, IL-8, and GM-CSF.  Further, this inhibition is a promising therapeutic
avenue and can significantly reduce primary tumor growth in xenograft models.  In
addition, preliminary data indicate that p38MAPK inhibition can reduce bone and
visceral metastasis in PyMT breast cancer metastasis model (data not shown). Around
90% of all cancer deaths are caused by metastasis.  In addition, bone metastases
dramatically decrease quality of life.  Thus, it is important to continue to study
p38MAPK’s role in metastasis and whether treatment with p38MAPK inhibitors, in
conjunction with chemotherapy, is an effective therapy option.  Importantly, our data
indicate that p38MAPK act on the tumor and metastatic microenvironment, not directly
on the tumor cells (Supp. Fig 3.1.b, Fig 3.1, & data not shown).
However, p38MAPK has also been reported to enforce tumor cell dormancy (13, 14).
Dormant tumor cells tend to be resistant to chemotherapy and may represent a
significant source of tumor recurrence.  While it is possible that inhibiting p38MAPK
could have negative outcomes via activation of otherwise dormant tumor cells, it is also
likely that treatment with p38MAPK inhibitors could sensitize dormant tumor cells to
137
chemotherapy by limiting their stromal support and/or driving them into the cell cycle.
Effective targeting of dormant tumor cells may reduce the chances of tumor recurrence.
To better assess the potential for p38MAPK inhibitors as anti-cancer therapeutics, more
work is needed to understand tumor dormancy and the microenvironment’s role in it,
metastasis, and the effects of p38MAPK inhibition.
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